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1 Introduction 
Since the early beginnings, in the 1950’s, hematopoietic stem cell transplantation 
(HSCT) is being performed as the major curative therapy for several life-
threatening hematological and genetic disorders. Huge advances have been 
made in the past 60 years for successful transplantation and to increase the 
quality of life of patients, yet, complete success is hard to achieve due to the 
frequent occurrence of a secondary disease called graft versus host disease 
(GvHD). The number of allogenic hematopoietic cell transplantations continues to 
increase with more than 25,000 allogenic transplantations performed annually1. 
1.1  Hematopoietic Stem Cell Transplantation (HSCT) 
Hematopoietic stem cells (HSCs) are pluripotent stem cells in the bone marrow 
(and fetal liver) that can give rise to all lineages of blood cells, including 
lymphocytes2. Mature blood cells are produced continuously by differentiation and 
expansion of hematopoietic stem cells. These stem cells have a unique capacity 
of self-renewal: they produce some daughter cells that do not differentiate, but 
replace and maintain the stem cell pool throughout individual’s life. Leukemic 
cells arise from malignant stem cells that usually originate via mutation of normal 
stem cells. Most of the leukemic cells have limited capacity for proliferation and 
are continuously replenished by leukemic stem cells. Only 1 in 1 million leukemic 
blasts appears to be a true stem cells, according to the capacity to propagate and 
sustain human leukemia in immunologically susceptible mice3. Chemotherapy 
may eradicate the majority of leukemic blasts; leukemic stem cells, however, are 
quiescent and insensitive to therapy4, and will result in recurrence. Some 
malignant stem cells survive even a lethal dose of total-body irradiation (TBI) and 
chemotherapy which is given as a preparative regimen for HSCT. The recurring 
malignant cells may be eliminated by immunologically active donor T cells and 
this phenomenon is called Graft vs Leukemia (GvL) effect5. Therefore HSCT 
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serves as promising therapy to get rid of leukemia and keep the immune system 
in balance but at the cost of GvHD.  
HSCT is an intensive curative therapy for several malignant and non-malignant 
diseases1. Following conditioning with irradiation or chemotherapy to eradicate 
leukemic cells and render the recipient receptive of new stem cells, patients are 
given infusion of hematopoietic stem cells from a suitable donor6.  
Table 1.1 summarizes some diseases commonly treated with allogenic 
hematopoietic stem cell transplantation7. 
  
 
Table 1.1: Diseases Commonly Treated with Allogenic Hematopoietic Stem 
Cell Transplantation 
Cancers Other Diseases 
Acute myeloid leukemia 
Acute lymphoblastic leukemia 
Chronic myeloid leukemia 
Myelodysplastic syndrome 
Myeloproliferative disorders 
Non-Hodgkin’s lymphoma 
Hodgkin’s disease 
Chronic lymphocytic leukemia 
Multiple myeloma 
Juvenile chronic myeloid leukemia 
Aplastic anemia 
Paroxysmal nocturnal hemoglobinuria 
Fanconi’s anemia 
Blackfan-Diamond anemia 
Thalassemia major 
Sickle cell anemia 
Severe combined immunodeficiency 
Wiskott-Aldrich syndrome 
Inborn errors of metabolism  
 
1.1.1  Selection of stem cell donors  
In order to achieve successful stem cell transplantation, it is crucial that both 
donor and recipient have a high degree of match in Human Leukocyte Antigen 
(HLA), a highly polymorphic protein that differs from individual to individual, 
encoded by Major Histocompatibility Complex (MHC). Class I HLA (A,B & C) are 
expressed on almost all nucleated cells and platelets whereas class II HLA 
proteins (DR, DQ & DP) are primarily expressed on cells that arise from 
hematopoietic stem cells such as B cells, monocytes and dendritic cells, but can 
be induced on other cell types during immune response1. The HLA system 
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encodes structurally homologous cell surface glycoproteins which present 
peptides to the immune cells that trigger an immune response and are encoded 
by chromosome 6, characterized by a high degree of allelic polymorphism. The 
strongest transplant reactions occur when the HLA of the donor and the recipient 
are incompatible7. Therefore the best donor for HSCT would be an HLA matched 
sibling. When a recipient does not have any siblings, a matched unrelated donor 
(MUD) is chosen based on at least HLA-A, -B, -C and –DRB1 alleles. Allele 
compatibility for the HLA-A/B/C/DRB1//DQB1 loci is defined as a 10/10 match 
and considered as the standard donor requested by many transplant centers8. 
Despite HLA identity between donor and recipient, almost 40% of patients 
receiving HLA-identical grafts develop GvHD due to genetic differences that lie 
outside of the HLA-loci, in terms of minor histocompatibility antigens (mHags)1. 
mHags are immunogenic peptides derived from polymorphic cellular proteins. 
These peptides bind to HLA antigens and are recognized by allogenic T cells.  
1.1.2 Sources of Stem Cells 
HSCs can be obtained either directly from bone marrow, from peripheral blood or 
from umbilical cord blood. Since marrow stem cells detach continuously and 
circulate in the peripheral blood, peripheral blood stem cells (PBSCs) are the 
most convenient source of hematopoietic stem cells. In allogenic stem cell 
transplantation, PBSCs are thought to have better and rapid hematopoietic 
reconstitution and have the potential to reduce disease recurrence9 . However, 
PBSCs contain more T lymphocytes than the bone marrow, thus increase the 
incidence and prolong the treatment of chronic GvHD (cGvHD)10,11.  
The use of cord blood as an alternative to donor stem cells has provided a 
promising alternative when transplantation is urgent or when the suitable donor is 
not found7. Blood from the umbilical cord and placenta of newborn child is rich in 
hematopoietic stem cells but the numbers of cells are limited. Infection is a 
common problem after cord blood transplantation since hematological and 
immune reconstitution is slower in cord blood transplantation. However this type 
of transplantation requires less-stringent HLA matching12 compared to marrow or 
peripheral blood.  
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1.1.3  Conditioning therapy for HSCT 
For successful HSCT, a first criterion is that the graft gets enough space and 
support for cell proliferation and differentiation. Therefore, the existing host stem 
cells must be eradicated in order for donor stem cells to engraft properly for which 
conditioning therapy is necessary prior to HSCT. Secondly, it is crucial that 
recipients are immunocompromised to prevent rejection of the incoming donor 
cells by the host immune system. The administered conditioning regimen 
suppresses the host immune system and thus, allows donor stem cells to home in 
the bone marrow microenvironment without the risk of graft rejection. Finally and 
most importantly, the conditioning therapy eradicates the underlying disease and 
provides long-term disease control or at least reduces leukemic cells to a level 
which allows final elimination by GvL effects. This is particularly important for 
patients with hematological malignancies.  
 
Although there is no full agreement on meticulous classification of conditioning 
treatments, generally accepted definitions are of three types: myeloablative 
conditioning, non-myeloablative and reduced-intensity conditioning13. The 
diagrammatic overview of conditioning is shown below in Figure 1.1. 
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Figure 1.1: Overview of myeloablative and non-myeloablative conditioning 
regimens  
Lightning bolts in yellow represent total body irradiation and the ovals in red 
represent chemotherapy5. 
 
Myeloablative (MA) conditioning is of high-dose intensity consisting of a single 
agent or combination of agents that eradicate the patient’s hematopoietic cells in 
the bone marrow and induce long-lasting trilineage aplasia. This strategy includes 
TBI and/or alkylating agents, at doses that will not allow autologous hematologic 
recovery resulting in profound pancytopaenia  within days from the time of 
administration13. Pancytopaenia  is life-threatening and fatal unless patients’ 
hematopoiesis is restored by infusion of hematopoietic stem cells.  
Non-myeloablative (NMA) conditioning can be defined as a regimen that will 
cause minimal cytopenia, little early toxicity and does not require hematopoietic 
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stem cell support13,14. Nevertheless, NMA conditioning regimens are 
immunosuppressive to the extent that, when followed by granulocyte-colony 
stimulating factor (G-CSF) mobilized PBSC or BM infusion, donor 
lymphohematopoietic cells can engraft with at least mixed donor/recipient 
chimerism15. The final elimination of host hematopoiesis is then achieved by graft-
versus-hematopoietic and GvL effects of the donor immune cells resulting 
eventually in full donor chimerism14.  
Reduced intensity conditioning (RIC) regimens try to fill the gap between MA and 
NMA conditioning therapies and are used for the majority of patients nowadays. 
The concept of RIC is based on the idea of preventing the high toxicity and 
mortality associated with MA conditioning regimens in patients with advanced age 
or relevant comorbidities16. The goal of RIC is not always complete tumor 
eradication and thus, complete destruction of host hematopoiesis but sufficient 
control of the underlying disease by cytotoxic therapy followed by the immune-
mediated effects of donor graft cells16.  
Table 1.2 summarizes the current, most frequently used conditioning regimens for 
allogeneic HSCT. 
 
Table 1.2: Frequently used Conditioning Regimens in various Transplant 
Centre Worldwide 
Intensity Regimen Comments 
Myeloablative  
CY/TBI Profound pancytopenia, 
require stem cell support, 
substantial nonhematological 
toxicities 
BU/CY 
Non-myeloablative  
FLU/TBI 
Minimal cytopenia, do not 
require stem cell support 
TLI/ATG 
Low dose TBI 
Reduced-Intensity  
FLU/MEL 
Intermittent cytopenia, reduced 
nonhematological toxicities 
FLU/BU 
FLU/CY 
 
Abbreviations: CY = cyclophosphamide; TBI = total body irradiation; BU = 
busulfan; FLU = fludarabine; TLI = total lymphoid irradiation; ATG = anti-
thymocyte globulin; MEL = melphalan. 
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1.2 Graft versus Host Disease (GvHD) 
GvHD is the most recognized complication after HSCT. The first recognition of 
GvHD was in 1956 in a murine model. Barnes et al.. demonstrated that irradiated 
mice infused with the allogenic marrow and spleen cells recovered from radiation 
injury and aplasia but they developed diarrhea, weight loss, skin changes and 
liver abnormalities. Mice subsequently died due to “secondary disease”17. This 
phenomenon was subsequently recognized as graft versus host disease (GvHD). 
A decade later, in 1966, Billingham postulated three crucial requirements for the 
development of GvHD: 
 i) the transplanted graft must contain immunologically competent cells, 
 ii) the recipient must be incapable of rejecting or eliminating transplanted cells 
and,  
iii) the recipient must express tissue antigen that are not present in the 
transplant donor thus the recipient antigen be recognized as foreign by donor 
cells18.  
Today it is realized that the immunocompetent cells are T lymphocytes that are 
present in the stem cell inoculum and are required to mount an effective immune 
response19. A normal immune system is able to reject T cells from a foreign 
donor, but when the patient immune system is compromised by the use of various 
immune-ablative agents (chemotherapy and/or radiotherapy), the recipient is 
incapable of rejecting transplanted cells20. Previously it was believed that acute 
GvHD occurs within day 100 after transplantation and chronic GvHD occurs 
beyond day 100 and that the most affected organs at the onset of GvHD are skin 
(81%), gastrointestinal tract (54%) and liver (50%)21. Now it is clear that acute 
GvHD can occur after day 100 as late acute GvHD (e.g. after cessation of 
immunosuppression or after donor lymphocyte infusion) or cause an overlap 
syndrome of both acute and chronic GvHD22.  
1.2.1 Pathophysiology of acute GvHD: a three-step model 
Acute GvHD has been attributed to three stages. Initially there is tissue damage 
due to conditioning which in turn activates the host antigen presenting cells 
(APCs). Secondly, APCs activate donor T cells, also known as afferent phase. 
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Finally, in the efferent phase, cellular and inflammatory factors work together to 
destroy the target organs.  
a. conditioning-mediated tissue damage: damaged host tissue release danger 
signals that includes pro-inflammatory cytokines like tumor necrosis factor (TNF) 
and interleukin-1 (IL-1)23, which can activate host APCs, ultimately activating 
donor T cells infused in the stem cell inoculum24,25. Conditioning-mediated 
damage to the GI tract remains the main concern as the GI tract allows systemic 
translocation of microbial products like lipopolysaccharide (LPS) and pathogen 
associated molecular patterns (PAMPs) that greatly amplify host APC 
activation26, leading to T cell activation.  
 
Figure 1.2: Conditioning mediated tissue damage (phase I) 
Radiotherapy and/or chemotherapy damage the gastrointestinal mucosa which 
causes the translocation of DAMPS and PAMPS leading to the release of pro-
inflammatory cytokines27. 
 
b. donor T cell activation (the afferent phase): graft versus host disease occurs    
when donor T cells become activated and respond to HLA differences on 
recipient’s cells1. Experimental models have proved that the host APCs are 
necessary and sufficient to activate donor T cells and initiate GvHD25,28. Donor T 
cell can recognize alloantigen either on host APC, known as direct antigen 
presentation29 or on donor APCs, known as indirect presentation30. T cell 
response depends on the disparity between the donor and the recipient with 
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regard to major and minor HLA1. CD4+ T cells respond to the variations in MHC 
class II molecules (HLA-DR, DQ, DP) and CD8+ T cells respond to the variations 
in MHC class I molecules (HLA-A, B, C)31. Even though the transplantation is 
carried out with a HLA matched donor, GvHD occurrence has been reported to 
occur due to differences in minor HLA32.  
 
Figure 1.3: Donor T cell priming and differentiation (phase II) 
Both donor and recipient APCs are actively involve in antigen presentation. 
Activation of T cells in the presence of various cytokines determines the fate of T 
cell differentiation. Th2, Th17 and Th1 marked by the transcription factors GATA-
3, RORyt and T-bet respectively27.  
 
c. target cell apoptosis (the efferent phase): in this phase, both innate and 
adaptive immune cells work synergistically to aggravate the T cells mediated 
inflammation. Cellular mediators such as cytotoxic T lymphocytes (CTLs) and 
natural killer (NK) cells use Fas/Fas ligand (FasL) pathway and perforin/granzyme 
pathway to lyse the target cells33,34. Furthermore, inflammatory cytokines 
synergize with CTLs, resulting in further tissue injury and possible target organ 
dysfunction1. In addition, microbial products like LPS, which are released during 
conditioning, leak through a damaged intestinal mucosa and skin, and stimulate 
mononuclear cells (monocytes/macrophages) to secret inflammatory cytokines. 
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This leads to amplification and propagation of the so-called “cytokine storm”1 and  
to the destruction of epithelial cells mostly in the GI tract.  
 
Figure 1.4: Target cell apoptosis: the effector phase (phase III) 
 Liver, lung, skin and most pronouncedly gut are the target tissue of T cells27,35.  
 
 In the last 10 years, this concept has been largely extended and a more 
differentiated view has been adapted. It became clear that the microbiota of 
epithelial tissues are major players influencing epithelial integrity and local 
immune tolerance by commensal bacteria and millions of metabolites are 
produced to maintain epithelial homeostasis 36,37. 
In context with the concept of microbiota as important players, researchers have 
recognized the increasing importance of regulatory immune cells which normally 
balance immune reactions. Regulatory T cells expressing the transcription factor 
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Foxp3 occur as natural, thymus derived regulatory cells and are able to prevent 
alloreactions38. On epithelial surfaces, induced peripheral Tregs try to dampen 
acute inflammation39. Foxp3+ T cells act in cooperation with numerous newly 
identified regulatory populations such as invariant NKT cells40, myeloid derived 
suppressor cells and a whole new set of innate immune cells such as innate 
lymphoid cells41. 
.  
1.3 Regulatory T cells (Tregs) in GvHD 
Tregs are a subset of CD4+ T cells whose function is to suppress immune 
responses and maintain self-tolerance42. A transcription factor called FOXP3, a 
member of the fork head family of transcription factors, is critical for the 
development and function of Tregs and is used as a definite marker to identify 
Tregs42,43. Tregs are produced in the thymus as a functionally mature 
subpopulation of T cells and can also be induced from naive T cells in the 
periphery44.  
Natural Tregs (nTregs), derived from the thymus are characterized by the co-
expression of CD4, CD25 and Foxp3, collectively represented as 
CD4+CD25+Foxp3+ Tregs45. Induced or adaptive Tregs (iTregs) are generated in 
the peripheral lymphoid organs in presence of transforming growth factor beta 
(TGF-B)46.  
1.3.1  Tregs in immune balance 
Tregs are known to downregulate immune responses by a) production of 
inhibitory cytokines and b) a contact-mediated effect on APCs. Tregs produce the 
anti-inflammatory cytokine- interleukin 10 (IL-10), that inhibits the production of IL-
12 by activated DCs and macrophages47,48. IL-10 also inhibits the expression of 
co-stimulators and class II MHC molecules on DCs and macrophages thus 
inducing tolerance of immune system47-49. Another anti-inflammatory cytokine 
produced by Tregs, TGF-β, inhibits the proliferation and effector functions of T 
cells and the activation of macrophages. TGF-β also regulates the differentiation 
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of functionally distinct subsets of T cells, stimulates production of immunoglobulin 
A (IgA) antibodies, promotes tissue repair after local immune and inflammatory 
reactions subside, conferring Tregs mediated immune reconstitution47-50. Tregs 
play a major role in regulation of epithelial inflammation and are strongly 
influenced by the interaction with the epithelial microbial environment36,51.  
 
1.3.2 Tregs in pre-clinical model of Stem Cell Transplantation. 
Tregs play an indispensable role in both solid organ transplant tolerance and in 
allograft tolerance after HSCT. In rodents and humans, a subpopulation of 
thymus derived naïve CD4+ T cells that co-express the IL-2Ralpha chain, CD25, 
has potent suppressor activity. Tregs mediate transplantation tolerance in 
experimental models of skin, solid organs52 as well as tolerance to bone marrow 
allografts53. HSCT and conditioning can cure malignant and non-malignant 
hematological disorders ,but at the same time the treatment efficacy is highly 
limited due to GvHD1. Regulatory T cells have received considerable attention in 
recent science due to their ability to suppress the proliferation of conventional T 
cells and prevent GvHD in animal models when added to donor grafts containing 
conventional T cells, hence suppressing GvHD54. Using a mouse model, Edinger 
and co-workers have shown that CD4+CD25+ Tregs suppress GvHD after bone 
marrow transplantation without abrogating the graft versus-leukemia (tumor) (GvL 
or GvT) effect38 supporting the importance of Tregs in allogenic HSCT. It has 
been demonstrated that the adoptive transfer of Tregs preserved thymic and 
lymphoid architecture of the host and hence accelerate post-transplant T cell 
immune reconstitution in a murine GvHD model55.  
 
Tregs are long believed to be a subset of CD4+ T cell compartment. Recently,  
CD8+ Treg population was reported and ws shown to be capable of suppressing 
T cell responses in an experimental model of autoimmunity56. In terms of GvHD, 
Robb et al.. demonstrated that CD8+Foxp3+ Tregs suppressed GvHD and 
attenuated GvHD mortality after bone marrow transplantation (BMT) in mice 
model57.  
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1.3.3 Tregs in clinical Hematopoietic Stem Cell Transplantation 
Many researchers have focused on evaluating the status of Tregs after HSCT, 
since they play an important role in the amelioration of GvHD. Using peripheral 
blood of patients after transplantation, Li et al. demonstrated that the frequency of 
CD4+CD25+ Tregs was significantly downregulated in patients with severe acute 
or chronic GvHD 58. They also showed that a decreased level of CD4+CD25+ 
Tregs was correlated to increased severity of GvHD 58. While majority of studies 
focused on blood-derived Tregs, there is little information on Tregs isolated from 
intestinal tissues due to the lack of availability of repeated gut biopsies without 
diagnostic purpose. Using immunoenzymatic labeling, Rieger et al. were the first 
to demonstrate that the infiltrating Tregs decreased the signs of acute and chronic 
GvHD in intestinal mucosa 59. They showed that the acute and chronic GvHD 
patients had a complete lack of counter regulation indicated by a Foxp3+/CD8+ T 
cell ratio in patients with GvHD identical to that of healthy individuals, while this 
ratio was increased in patients without GvHD59.  
However, for the first time, Lord et al. demonstrated a contradictory result 
showing that Foxp3+ cells were nither decreased in blood nor in gastrointestinal 
tissues and that the frequency of Tregs did not correspond to the disease 
incidence or severity 60. They rather found that the Foxp3+ cells were significantly 
upregulated in GvHD intestinal mucosa when compared to non GvHD mucosa60. 
This finding is further supported by Ratajczak et al. who observed an increased 
proportion of CD4+Foxp3+ cells in Grade 2-4 GvHD patients compared to grade 0-
1 GvHD patients61. Part of these conflicting results is again due to the lack of 
possibility to discriminate between natural and induced Tregs. It may well turn out 
that nTregs are decreased in GvHD while iTregs try to compensate for 
exaggerated inflammation.  
 
1.3.4 Approaches to induce regulatory T cells after HSCT 
Tregs are crucial to induce tolerance and maintain immune homeostasis. A major 
challenge to use Tregs as a therapy is their relative scarcity in blood (0.5-1% of 
CD4+CD25 bright T cells)62. In 2011, Hippen et al. showed two individual reports 
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regarding generation of induced Tregs in large scale63 and ex vivo expansion of 
natural Tregs64, both method focused on the development of large scale 
expansion protocols for Tregs with higher cellular yield so that they can ultimately 
be used as GvHD therapy or for GvHD-prevention63,64. Using chronic GvHD 
subjects, Matsuika and co-workers reported that daily administration of low-dose 
IL-2 induced selective expansion of functional Tregs, improved cGvHD, restored 
CD4+ T cells homeostasis, and promoted the re-establishment of immune 
tolerance65. This suggests that low-dose IL-2 could be a potential therapy to 
restore immune balance after HSCT.  
Furusuwa and colleagues reported that the clostridia products like short chain 
fatty acid (SCFA) especially butyrate can induce the differentiation of colonic 
Tregs in-vitro and in vivo in mice66 providing strong evidence of the necessity of 
host-microbiome interaction to establish immunological tolerance and 
homeostasis in gut. Moreover, Mathewson and colleagues reported that restoring 
clostridia metabolites or the strain itself modulated intestinal epithelial cell integrity 
and mitigated GvHD in mice36. Of note, Baban and colleagues reported 
indoleamine 2,3-dioxygenase (IDO) as a potent inducer of Tregs and an inhibitor 
of Th1 cell subset67. Later it was reported that Tregs generation by IDO takes 
place via aryl hydrocarbon receptor (AhR)68. Interestingly, it was recently 
observed that AhR engages in long-term regulation of systemic inflammation only 
in presence of IDO69 suggesting a triangular positive feedback loop between 
Tregs, IDO and AhR. AhR is a ligand activated transcription factor that is 
activated in presence of xenobiotic compounds and bacterial metabolites such as 
indole and its derivate70. Taken together, these findings strongly suggest that right 
balance of gut microbiome is crucial to induce Tregs for intestinal tolerance. 
 
1.3.5 Tregs in GvHD: First-In-Man Clinical Trial  
The first clinical trial reported was an adoptive transfer of ex-vivo expanded 
CD4+CD25+CD127- Tregs after HLA-identical sibling HSCT. Transfer of Tregs 
resulted in a reduction of the steroids administered, increase in levels of 
circulating Tregs and a decrease in inflammatory cytokine levels in the peripheral 
blood (PB)71. Another “first-in-human” clinical trial was reported in double 
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umbilical cord blood transplantation (UCBT) in 23 patients, who received in-vitro 
expanded Tregs derived from partially HLA-matched third-party UCB units. There 
was an almost significant reduction of the incidence of grade II-IV acute GvHD 
controls without transfusion of Tregs. No toxicities were observed, no infections, 
relapse or early mortality which suggested that UCB Tregs could be a potential 
tool for preventing acute GvHD72. Taken together these early trials suggest the 
potential of Tregs as candidates to ameliorate GvHD and establish immune 
reconstitution after transplantation in larger clinical trials. 
1.4 Indoleamine-2,3 dioxygenase (IDO) in GvHD 
IDO is an intracellular enzyme that catalyzes the first and rate-limiting step of  
essential amino acid tryptophan catabolism73. This immunosuppressive enzyme 
is expressed by APCs and parenchymal cells and is further inducible by 
inflammation74. Depletion of tryptophan and the increase of tryptophan 
metabolites (namely kynurenines) via IDO inhibit T cell proliferation and ultimately 
favor T cell apoptosis. Moreover, tryptophan starvation and the presence of 
kynurenines induces the conversion of naïve T cells and regulatory T cells75. Of 
interest, Mezrich and co-workers demonstrated that kynurenine mediated Tregs 
generation takes place via AhR activation68. Immunosuppressive properties of 
IDO have been well defined in maternal-fetal acceptance, tumor immunity, 
autoimmunity and chronic infections76. Figure 1.5 shows IDO mediated 
tryptophan degradation and effect on T cells77.  
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Figure 1.5: Tryptophan degradation by IDO 
IDO induce tryptophan degradation which results in inhibition of T-cell 
proliferation, increase in T-cell apoptosis, and de novo formation of Tregs77. 
 
In the context of GvHD, experimental models have well established IDO as a 
critical regulator of GvHD. IDO knock-out mice showed increased colon GvHD 
and reduced survival after allogenic stem cell transplantation when compared to 
wild-type mice74. In a clinical context, GvHD patients tend to have increased IDO 
production which reflects a reactive release of immunosuppressive mediators in 
GvHD related inflammation, that is perhaps initiated to balance immune 
reactions78. IDO is well-known to induce peripheral tolerance by increasing 
regulatory T cells79,80. In terms of protective effect in GvHD, apart from Tregs and 
IDO positive cells, a new type of immune cell-innate lymphoid cells has gained 
substantial importance in the past few years. 
 
1.5 Innate lymphoid cells (ILC) in GvHD 
ILCs are a recently identified family of mononuclear hematopoietic cells that 
preserve epithelial integrity and tissue immunity throughout the body 81. These 
cells are derived from Common Lymphoid Progenitor (CLP) and combines innate 
and adaptive modes of function 82. With recent advances in understanding the 
development and proliferation of ILCs, they are classified into 3 groups. ILCs 
group 1, ILCs group 2 and ILCs group 3.  
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The group 1 ILCs comprises cells that produce type 1 cytokines like IFN-y 83 and  
aredependent on transcription factor T-bet for development . Initially, conventional 
(c) NK cells were classified in group 1 ILC since they express T-bet and produce 
significant amount of IFN-y. However, cNK cells turn out to differ from other group 
1 ILC subset as they are developmentally dependent on Eomesodermin (Eomes, 
a T box transcription factor related to T-bet) but not on T-bet 84.  
 
Innate lymphoid cells that predominantly produce type 2 cytokines are termed as 
group 2 ILCs or ILC2s 85. ILC2s produce very high amount of IL-5 and IL-13, and 
also IL-9, IL-4 and GM-CSF86,87. These cytokines are vital for mucus production 
from goblet cells, eosinophils induction, muscle contraction, mastocytosis 88,89 
and ILC2 produced amphiregulin is crucial for tissue repair90. ILC2s are 
developmentally dependent on the  transcription factors retinoic acid receptor-
related orphan receptor-a (RORa) 91 and GATA- binding protein 3 (GATA3) 92. 
 
Group 3 ILCs are defined by the expression of transcription factor RORT 
(RORC) for their development and expression of NK cell activating receptor 
NKp46 but are distinct from NK cells93-95. ILC3s are able to produce cytokines IL-
17A and /or IL-22 85. ILC3s are divided into Lymphoid Tissue inducer (LTi) cells 
that expresses IL-17 and IL-22, natural cytotoxicity receptor (NCR) positive IL-22 
producing ILC3s and NCR negative IL-17 producing ILC3s 83.  
ILC3s has gained substantial focus ever since the discovery that IL-22 producing 
ILC3s are indispensable for mucosal immunity95,96. In particular, ILC3s are the 
major source of IL-22 cytokine that are protective to epithelial cells in the intestine 
97. These cell types are activated directly by bacterial metabolites via aryl 
hydrocarbon receptor (AhR) or indirectly through myeloid cells mediated cytokine 
IL-23 98. Studies of ILC3s on human gut are highly missing due to the lack of 
specific marker for ILCs, however, mice experiments have revealed that ILC3s 
play a crucial role in gut immunity by directly inducing epithelial cell proliferation, 
promoting epithelial cell mediated production of anti-inflammatory cytokines and 
antimicrobial peptides like Reg3a, preventing dissemination of commensal 
bacteria, and suppressing microbiota-specific pro-inflammatory CD4+ T cell 
responses 99. Figure 1.6 shows the development of innate lymphoid cells100 
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Figure 1.6: Development of Innate Lymphoid Cells. 
In fetal liver or in adult bone marrow, ILCs differentiate from common lymphoid 
progenitor (CLP) in presence of transcription factor Id2. NK cell precursor gives 
rise to innate NK cells and ILC precursor gives rise to T-bet dependent ILC1s, 
GATA-3 dependent ILC2s and RORyt dependent ILC3s100.  
 
1.6 IL-17 in GvHD 
Ubiquitously known as Th-17 cell cytokine, IL-17 is a pro-inflammatory cytokine 
known to mediate protection again extracellular pathogens, and promotes 
inflammatory pathology in autoimmune disease 101. The inflammatory properties 
of IL-17 have gained a substantial importance in development of GvHD in recent 
years102-104. IL-17 production is regulated by transcription factor RORT 105, an 
orphan nuclear receptor that drives the differentiation of Th17 cells.  
Although IL-17 is defined as Th-17 cytokine, Th-17 pathway is inadequate to 
explain the early IL-17 mediated immunity that have crucial roles during stress 
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responses and host defense especially when the IL-17 mediated immune 
pathway is induced within hours in response to epithelial cell injury or activation of 
pattern recognition receptors (PRRs)106-108, and this short time is not enough for 
the development of Th-17 cells. Therefore it is possible that the innate source of 
IL-17 exists and perhaps these cells in parts mediate regulation instead of 
inflammation. Furthermore, the inflammatory role of IL-17 in development of 
GvHD has been now challenged since the discovery of innate lymphoid cells 83. In 
brief, table 1.2 presents an overview of some IL-17 producing cells 109. 
 
  
Table 1.3: Innate IL-17 producing cells 
 
 
1.7 Microbial metabolites in GvHD 
Human gastro-intestinal tract harbors trillions of microbes that are fundamental for 
well-being of their host. These microbes are necessary to educate and discipline 
the human immune system. The diversity and complexity of the gut microbiota 
can be evaluated by using 16S ribosomal RNA (rRNA) sequencing 110 
technology. By now it is not surprising to see that the alteration of microbiome is 
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associated with cutaneous problems, gastric associated diseases, colorectal 
cancer, inflammatory bowel disease, liver complications, obesity, rheumatoid 
arthritis, and many more in the queue 111. In the context of allogenic stem cell 
transplantation, 16S rRNA sequencing revealed the major microbiome shift in the 
course of ASCT 112. Interestingly, there was huge predominance of Enterococcus 
species in patient with GvHD compared to non-GvHD patients 112. Surprisingly, 
authors also shed light on the decrease of microbial metabolite indoxyl sulfate 
which occurred as a consequence of loss of bacterial diversity 112. A more recent 
study proposed the loss of bacterial diversity and the decrease in urinary indoxyl 
sulfate in ASCT patients was associated with higher transplant related 
mortalityand poor survival 113. , detection of higher indoxyl sulfate in urine of 
patients was associated with presence of clostridia species 113. Collectively these 
finding suggests that the balanced microbial population and thereof, the bacterial 
metabolites may be important for immune mediated complications like GvHD.  
Other bacterial metabolites like butyrate, a short chain fatty acid that is produced 
by bacteria as a result of dietary fiber degradation, has been implicated in 
maintaining integrity of intestinal epithelial cell and reduces the severity of GvHD 
36. Among several short chain fatty acid receptors, butyrate receptor GPR109a is 
known to be involved in butyrate mediate suppression of inflammation114. 
GPR109a signaling promotes anti-inflammatory properties in myeloid cells 
thereby generating regulatory T cells, promotes IL-18 production by epithelial cell 
which collectively suppress inflammation and promotes immune regulation114. 
Moreover, bacterial metabolite indole has also been shown to strengthen 
epithelial barrier and reduce mucosal inflammation115,116. Due to immense 
importance of balanced microbial diversity, it has been suggested that prebiotics, 
probiotics and post biotics approach could benefit the patients while sparring 
antibiotic approach 37. Figure 1.8 shows the diagrammatic representation of 
possible clinical intervention of gut microbiota 37 
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Figure 1.7: Clinical intervention of gut microbiota 
Green box shows approaches to maintain healthy and balanced gut microbiome. 
Red box shows factors to destroy and alter microbiome37. 
1.8 Conclusion 
Despite of broad understanding, a major issue in treatment of especially aGvHD 
is that most approaches are started too late, when major changes have already 
severely damaged the target tissue. Therefore, biomarkers allowing early 
identification of patients at high risk are needed. A handful of biomarkers have 
been discovered which might be used to guide treatment in the future 117.  
The pathophysiology of aGvHD seems to be much more complex than our 
understanding due to the rising fact that bacterial diversity and bacterial 
metabolites plays crucial role in immune balance. Almost 1.5 million of bacterial 
metabolites are believed to be present in human immune system, effectively 
regulating both immune reaction and immune tolerance, ultimately deciding the 
fate of immune homeostasis. It is now of crucial importance to better understand 
the role of commensals in human health and therefor perhaps modulating 
bacteria and bacterial metabolites could be established as an alternative safe 
approach in future to improve the quality of life of GvHD patients.   
Finally, practice of stem cell transplantation differs from countries, and within a 
same country, it differs from transplantation institutes. Approaches aiming at 
standardization of diagnosis and treatment are urgently needed and addressed 
by several consensus projects118,119.   
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2 Research Objectives 
Graft versus host disease (GvHD) accounts for significant morbidity and mortality 
after allogenic stem cell transplantation (ASCT). Early diagnosis of the disease 
provides clinicians a better strategy for treatment of patients to improve the 
quality of life after ASCT. Histological evaluation of apoptotic changes in the 
biopsies of affected organs, especially skin and gastrointestinal (GI) tract is so far 
the gold standard for the diagnosis of GvHD. Apoptosis of target organs are 
largely mediated by donor immune cells that infiltrates to skin and GI tract. The 
overall aim of this study was to analyze immune cell infiltrates and biomarkers 
during acute GI GvHD. 
The specific aims of this dissertation were 
1) to assess immunoregulation in intestinal biopsies of patients after allogeneic 
SCT in relation to presence of GvHD and outcome by two different approaches. 
First, CD4+ and CD8+ T cell infiltrates in GI tract of patients after ASCT were 
quantified using single antibody immunohistochemistry (IHC). In order to analyze 
functional changes at tissue level, Foxp3, IDO and IL-17 was accessed with IHC. 
Further characterizations of cellular source of Foxp3+ and IL-17+ cell were 
performed by double immunofluorescence. In a second approach, PCR was 
performed to analyze FOXP3, IDO and RORC at transcriptional level in order to 
confirm results obtained by protein expression. 
2) to assess whether tissue markers of the GI tract can be used as biomarkers in 
patients. In addition to the described analyses, a panel of carefully selected 
messenger RNAs was analyzed in GI tract of transplanted patients in 
collaboration with Medical University Göttingen to identify possible new 
biomarkers of GvHD and outcome. 
3) to characterize the functional role of the bacterial metabolite indoxyl sulfate 
with respect to immunoregulation in cultured dendritic cells in order to highlight 
the functional importance of bacterial metabolites. 
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3 Materials  
 
3.1 Equipments 
 
Autoclave  Technomara, Fernwald, Germany 
Bioanalyzer 2100 Agilent Technologies, Böblingen, Germany 
CASY Cell Counter Innovatis/Roche, Basel, Switzerland 
Centrifuge Sigma 2 Sartorius, Göttingen, Germany 
Electrophoresis equipment  Biometra, Göttingen, Germany 
ELISA plate reader MWG Biotech, Ebersberg, Germany 
EVOS Cell Imaging System Life Technologies, Carlsbad, CA, USA 
FACS Calibur flow cytometer BD Biosciences, Franklin Lakes, NJ, USA 
Forceps Aesculap, Tuttlingen, Germany 
Fluidigm  Fluidigm, South San Francisco, CA, USA 
Heat sealer Eppendorf, Hamburg, Germany 
Hemocytometer Marienfeld, Lauda-Königshofen, Germany 
Incubators  Heraeus, Hanau, Germany 
Laminar Flow Cabinet Clean Air Telstar, Woerden, The Netherlands 
Microscopes Zeiss, Jena, Germany 
Multipipettor Multipette plus Eppendorf, Hamburg, Germany 
NanoDrop 1000 Thermo Fisher Scientific, Schwerte, Germany 
PCR Thermocycler PTC-200 MJ-Research/Biometra, Oldendorf, Germany 
pH Meter  Knick, Berlin, Germany 
Pipetboy Integra Biosciences, Fernwald, Germany 
Pipettes Gilson, Milddleton, WI, USA 
Pipettes Eppendorf, Hamburg, Germany 
Power supplies  Biometra, Göttingen, Germany 
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Realplex Mastercycler epGradient  Eppendorf, Hamburg, Germany 
Rocking plattform HS250 IKA Labortechnik, Staufen, Germany 
Sonifier 250  Branson, Danbury, CT, USA 
TissueFAXS TissueGnostics GmBH, Vienna, Austria 
TissueLyser Qiagen, Hilden, Germany 
Vortexer Scientific Industries Ink., Bohemia, NY, USA 
Water purification system  Millipore, Eschborn, Germany 
Waterbath Julabo, Seelstadt, Germany 
Western blot chamber Biometra, Göttingen, Germany 
 
3.2 Consumables 
Cell culture flasks Costar, Cambridge, MA, USA 
Cell culture plates BD, Franklin Lakes, NJ, USA 
Cell scrapers Sarstedt, Nümbrecht, Germany 
Combitips for Eppendorf multipette Eppendorf, Hamburg, Germany 
Cryo tubes  Corning, Corning, NY, USA 
Heat sealing film  Eppendorf, Hamburg, Germany 
HyperfilmTM ECL GE Healthcare, Chalfont St Giles, UK 
Immobilon-P PVDF membrane Millipore, Schwalbach, Germany 
Micro test tubes (0.5 ml, 1.5 ml, 2 ml)  Eppendorf, Hamburg, Germany 
Micropore filters Sartorius, Göttingen, Germany 
Microtiter plates (6, 12, 24, 96 wells) Costar, Cambridge, MA, USA 
Microtiter plates for ELISA Costar, Cambridge, MA, USA 
PCR plate Twin.tec 96 well Eppendorf, Hamburg, Germany 
Petri dish Falcon, Heidelberg, Germany 
Pipette tips Eppendorf, Hamburg, Germany 
Plastic pipettes Costar, Cambridge, MA, USA 
Polystyrene test tubes Falcon, Heidelberg, Germany 
Syringe Filters, sterile Sartorius, Göttingen, Germany 
Syringes and needles Becton Dickinson, Heidelberg, Germany 
Tubes (5 ml, 15 ml, 50 ml, 225 ml)  Falcon, Heidelberg, Germany 
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Whatman® Chromatography Paper Sigma-Aldrich, St. Louis, MO, USA 
 
3.3 Media, buffers and solutions 
 
2-Mercaptoethanol Gibco/Life Technologies, Carlsbad, CA, 
USA 
Acrylamide Carl Roth, Karlsruhe, Germany 
APS Merck Millipore, Billerica, MA, USA 
Aqua Braun 
Bovine serum albumin Sigma-Aldrich, St. Louis, MO, USA 
CasyTON Roche, Basel, Switzerland 
DMSO Sigma-Aldrich, St. Louis, MO, USA 
FACS clean BD Biosciences, Franklin Lakes, NJ, 
USA 
FACS flow BD Biosciences, Franklin Lakes, NJ, 
USA 
FACS rinse BD Biosciences, Franklin Lakes, NJ, 
USA 
Fetal calf serum Gibco/Life Technologies, Carlsbad, CA, 
USA 
Hydrogen peroxide Merck, Darmstadt, Germany 
HCl Carl Roth, Karlsruhe, Germany 
Isopropanol Braun 
L-Alanyl-L-Glutamine Merck Millipore, Billerica, MA, USA 
Methanol Thermo Fisher Scientific, Waltham, MA, 
USA 
Mounting media for 
immunohistochemistry 
Thermo Fisher Scientific, Waltham, MA, 
USA 
Nuclease-free water Gibco/Life Technologies, Carlsbad, CA, 
USA 
PBS Sigma-Aldrich, St. Louis, MO, USA 
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RPMI 1640 Gibco/Life Technologies, Carlsbad, CA, 
USA 
TEMED Sigma-Aldrich, St. Louis, MO, USA 
Triton X100 Sigma-Aldrich, St. Louis, MO, USA 
Tween 20 Sigma-Aldrich, St. Louis, MO, USA 
Trypsin-EDTA PAN Biotech, Aidenbach, Germany 
 
3.4 Chemicals 
All chemicals were purchased from Sigma-Aldrich (Taufkirchen, Germany) or 
Merck Millipore (Darmstadt, Germany) unless otherwise mentioned. 
 
 
3.5 Enzymes, kits, and reagents for molecular biology 
 
Agilent RNA 6000 Nano Kit Agilent Technologies, Santa Clara, CA, 
USA 
AmershamTM ECLTM Prime Western 
Blotting 
Detection Reagent 
GE Healthcare, Chalfont St. Giles, UK 
Aportinin Roche, Mannheim, Germany 
Bio-Rad  protein assay Bio-Rad, Munich, Germany 
dNTPs Roche diagnostics, Mannheim, 
Germany 
Ethidium bromide Sigma-Aldrich, St. Louis, MO, USA 
Foxp3 transcription factor staining 
buffer set 
eBioscience, San Diego, CA, USA 
GM-CSF Berlex, Seattle, USA 
LPS Enzo Life Sciences, Farmingdale, NY, 
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USA 
Human interleukin 4 (IL-4) Promokine, Heidelberg, Germany 
M-MLV Reverse Transcriptase Promega, Madison, WI, USA 
p-Coumaric acid Sigma-Aldrich, St. Louis, MO, USA 
Pepstatin Roche, Mannheim, Germany 
Proteinase K Roche, Mannheim, Germany 
QIAshredderTM Qiagen, Hilden, Germany 
QuantiFast SYBR® green PCR Kit Qiagen, Hilden, Germany 
Random Decamers Ambion/Life Technologies, Carlsbad, 
CA,USA 
RNAlaterTM Qiagen, Hilden, Germany 
RNase-free DNase Set Qiagen, Hilden, Germany 
RNeasy Mini Kit Qiagen, Hilden, Germany 
SDS Sigma-Aldrich, St. Louis, MO, USA 
 
3.6 Antibiotics 
Penicillin and streptomycin for primary cell culture were purchased from Gibco 
Life Technologies, Carlsbad, California, United States of America. 
3.7 Molecular weight standards 
For Western Blot bands, Kaleidoscope Prestained Standard from BioRad 
(Munich, Germany) was used as molecular weight standard for proteins. 
3.8 Oligonucleotides for qRT-PCR 
Unmodified, HPLC-purified oligonucleotides were designed using UCSC genome 
browser and Perl primer software. Primer sequences were purchased from 
Eurofins MWG Operon (Ebersberg, Germany). 
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3.9 PCR Primers 
3.9.1  Primers for RT-qPCR 
Genes Primer sequence 
18S rRNA 
Sense: ACC-GAT-TGG-ATG-GTT-TAG-TGA-G 
Antisense: CCT-ACG-GAA-ACC-TTG-TTA-CGA-C 
BATF 
Sense: GACAAGAGAGCCCAGAGGTG 
Antisense: TTCTGTGTCTGCCTCTGTCG 
DEFA5 
Sense: AGACAACCAGGACCTTGCTATCTC 
Antisense: GGTTCGGCAATAGCAGGTGG  
DEFB4 
Sense: AGTGAGAAGCGAATTTGAATTGGACAG 
Antisense: TGTATTCTTGGCTGCGACATTTCTTCC 
EGR2 
Sense: CACGTCCGGTGACCATCTTCCC 
Antisense: CCAGTCATGTCAATGTTGATCATGCC 
FOXP3 
Sense: GAAACAGCACATTCCCAGAGTTC 
Antisense: ATGGCCCAGCGGATGAG 
GPR109A 
Sense: GCGTTGGGACTGGAAGTTTG 
Antisense: GCGGTTCATAGCCAACATGA 
IDO1 
Sense: GGTCATGGAGATGTCCGTAAGGT 
Antisense: CCAGTTTCTTGGAGAGTTGGCAG 
RORC 
Sense: GCAGCGCTCCAACATCTTCTC 
Antisense: GCACACCGTTCCCACATCTC 
 
3.9.2 Primers for Fluidigm microarray (digital qPCR) 
Genes Sequences 
GAPDH 
 
Sense:  TTCGACAGTCAGCCGCATC 
Antisense: GCCCAATACGACCAAATCCGT 
AHR 
 
Sense: GGTTGTGATGCCAAAGGAAGAA 
Antisense: CGGATATGGGACTCGGCAC 
BATF 
 
Sense: GTGTGAGAGCCCGGAAGATT 
Antisense: ATCAGATGAGTCCTGTTTGCCA 
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CAMP 
 
Sense: GGTCCTCGGATGCTAACCTCT 
Antisense: TTCACCAGCCCGTCCTTCTTG 
CYP24A1 
 
Sense: TGTGCATTGGTCGCCGATTA 
Antisense: CAAATACCACCATCTGAGGCG 
CYP27A1 
 
Sense: GTGCATTGGTCGCCGATTAG 
Antisense: CAAATACCACCATCTGAGGCG 
CYP27B1 
 
Sense: ACGCTCTCTTGGGCTCTGTA 
Antisense: CACAGGGTACAGTCTTAGCACTT 
CYP2R1 
 
Sense: CCAGGTGTACGGAGAGATCTT 
Antisense: TCAACCCATCCTCGGCCATA 
DEFA5 
 
Sense: AGACAACCAGGACCTTGCTATCTC 
Antisense: GGTTCGGCAATAGCAGGTGG  
DEFB4A 
 
Sense: AGTGAGAAGCGAATTTGAATTGGACAG 
Antisense: TGTATTCTTGGCTGCGACATTTCTTCC 
EBI3 
 
Sense: AGAGCACATCATCAAGCCCG 
Antisense: AGCTCCCTGACGCTTGTAAC 
FOXP3 
 
Sense: GAA-ACA-GCA-CAT-TCC-CAG-AGT-TC 
Antisense: ATG-GCC-CAG-CGG-ATG-AG 
GATA3 
 
Sense: CTCTTCGCTACCCAGGTGAC 
Antisense: GGTTGTAAAAAGGGGCGACG 
GC 
 
Sense: GGCTACCACTTTTACATGGTCA 
Antisense: TCATAATCCCGGCCTCTCTCT 
GPR109A 
 
Sense: GCCCAACCTCTCCTTAAATAACC 
Antisense: GGAAACCTTAGGCCGAGTCC 
IDO1 
 
Sense: AGCCCCTGACTTATGAGAACA 
Antisense: AGCTATTTCCAACAGCGCCT 
IL10 
 
Sense: TGCTGGAGGACTTTAAGGGT 
Antisense: CGCCTTGATGTCTGGGTCTT 
IL12A 
 
Sense: ACCTCTTTTATGATGGCCCTGTG 
Antisense: CAGCTCATCAATAACTGCCAGC 
IL12B 
 
Sense: TTCATCAGGGACATCATCAAACCT 
Antisense: AGTACTCCAGGTGTCAGGGT 
IL17 
 
Sense: CCTCATTGGTGTCACTGCTAC 
Antisense: GGGGGAAGTTCTTGTCCTCAG 
Il22 
 
Sense: TATCACCAACCGCACCTTCA 
Antisense: GCGCTCACTCATACTGACTCC 
IL23 
 
Sense: CCCAAGGACTCAGGGACAACAG 
Antisense: AGTAGGGAGGCATGAAGCTGG 
IL33 
 
Sense: ACAGACTCCTCCGAACACAG 
Antisense: CTTTGGCCTTCTGTTGGGATTTTC 
PXR 
 
Sense: AACTTACCACCAAGCAGTCCAA 
Antisense: GGACCTCCGACTTCCTCATC 
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REG3a 
 
Sense: ATCCGCTGTCCCAAAGGCTC  
Antisense: AGCACAGACACCAGGTTTCCAG  
RORC 
 
Sense: GCAGCGCTCCAACATCTTCTC 
Antisense: GCACACCGTTCCCACATCTC 
TBET 
 
Sense: GGCGTCCAACAATGTGACCCA 
Antisense: TCTGGCTCTCCGTCGTTCAC 
TNF 
 
Sense: CTTTGGAGTGATCGGCCCC 
Antisense: GCTTGAGGGTTTGCTACAACA 
VDR 
 
Sense: GGCTACCACTTTTACATGGTCA 
Antisense: TCATAATCCCGGCCTCTCTCT 
.  
3.10  Antibodies 
3.10.1 Antibodies for Immunohistochemistry and 
Immunofluorescence 
Antibodies Species 
Dilution used 
in 
experiment 
Stock 
concentration 
Provider 
Foxp3 
Mouse 
monoclonal 
1:50 0.5 mg/ml eBioscience, CA, USA 
IDO clone 1F8.2 
Mouse 
monoclonal 
1:250 100 µg 
Millipore, Billerica, MA, 
USA 
IL-17 Goat polyclonal 1:25 0.2 mg/ml R&D 
CD3 clone SP7 
Rabbit 
monoclonal 
1:50 N/A Thermo Scientific 
CD4 clone SP35 
Rabbit 
monoclonal 
direct 2.5 µg/ml Ventana 
CD8 clone Sp57 
Rabbit 
monoclonal 
1:2 2.5 µg/ml Ventana 
CD117 
Rabbit 
polyclonal 
1:400 11.7 g/L Dako, Glostrup, Denmark 
CD127 
Rabbit 
polyclonal 
1:150 0.82 mg/ml Abcam, Cambridge, UK 
CD127 
Mouse 
monoclonal 
 0.5 mg/ml Novus 
Myeloperoxidase Rabbit 1:500 3.3 g/L Dako, Glostrup, Denmark 
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polyclonal 
 
Secondary antibodies  
Fluorescein Species 
Dilution used 
in experiment 
Stock Provider 
AF 488 (A11029) Goat anti mouse 1:75 2 mg/ml 
Invitrogen, Carlsbad, 
CA, USA 
AF 488 (A21467) Chicken anti goat 1:75 2 mg/ml 
Invitrogen, Carlsbad, 
CA, USA 
AF 546 (A10040) Donkey anti rabbit 1:75 2 mg/ml 
Invitrogen, Carlsbad, 
CA, USA 
AF 594 (A21201) 
Chicken anti 
mouse 
1:150 2 mg/ml 
Invitrogen, Carlsbad, 
CA, USA 
AF 594 (A11012) Goat anti rabbit 1:150 2 mg/ml 
Invitrogen, Carlsbad, 
CA, USA 
AF 594 (A21442) Chicken anti rabbit 1:150 2 mg/ml 
Invitrogen, Carlsbad, 
CA, USA 
AF 647 (A21443) Chicken anti rabbit 1:75 2 mg/ml 
Invitrogen, Carlsbad, 
CA, USA 
 
3.10.2 Antibodies for Flow cytometry 
All the antibodies used for flow cytometry were raised in mouse against human 
unless mentioned. 
Specificity Isotype Fluorochrome Clone Manufacturer 
CD1a Mouse IgG1 PE 
SFCI19Thy1A8 
 
Beckman Coulter, CA, 
USA 
 
CD80 Mouse IgG1 APC 
2D10 
 
Biolegend, CA, USA 
CD83 Mouse IgG1 PE-Cy7 
HB15e 
 
eBioscience, CA, USA 
 
CD86 Mouse IgG1 FITC 
2331( FUN-1) 
 
BD, Franklin Lakes, NJ, 
USA 
HLA-DR Mouse IgG2a FITC 
B8.12.2 
 
Beckman Coulter, CA, 
USA 
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CD4 Mouse IgG1 PE 
RPA-T4 
 
BD, Franklin Lakes, NJ, 
USA 
CD8 Mouse IgG1 FITC 
SK1 
 
BD, Franklin Lakes, NJ, 
USA 
CD25 Mouse IgG1 PE-Cy7 
M-A251 
 
BD, Franklin Lakes, NJ, 
USA 
CD62L Mouse IgG1 APC 
DREG-56 
 
BD, Franklin Lakes, NJ, 
USA 
Foxp3 Rat IgG2a APC 
PCH101 
 
eBioscience, CA, USA 
 
Annexin  FITC  
BD, Franklin Lakes, NJ, 
USA 
7-AAD 
 
 APC  
BD, Franklin Lakes, NJ, 
USA 
 
3.10.3 Antibodies for Elisa 
Capture, standard, and detection antibodies for Elisa were purchased from R&D, 
MN, USA 
3.10.4 Antibodies for Western Blot 
Antibodies Species Dilution  Molecular weight Provider 
iKBß Rabbit 1:1000 45 kDa 
Santa Cruz Biotechnology, Dallas, 
TX, USA 
Phosphor AKT Rabbit 1:1000 60 kDa 
Cell Signaling Technology, 
Danvers, MA, USA 
ß-Actin Rabbit 1:2000 42 kDa 
Sigma-Aldrich, St. Louis, MO, 
USA 
Rabbit-HRP Goat 1:2500  Dako, Glostrup, Denmark 
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3.11  Databases and Softwares 
The following databases and software tools were used to design experiments and 
process data, respectively. If no version is stated, the detailed information can be 
found in the corresponding methods chapters. 
 
AxioVision Rel 4.8 http://carl-zeiss-axiovision-
rel.software.informer.com/4.8/ 
EndNote X7 Thomson Reuters, New York, NY, USA 
FlowJo v9.5.3 FlowJo,LLC, Ashland, OR, USA 
Fluidigm real time PCR 
analysis 
https://www.fluidigm.com/software 
GeneRunner version 3.05 http://www.generunner.com 
GraphPad Prism 5.02 GraphPad Software, La Jolla, CA, USA 
ImageLab v4.0 Bio-Rad, Munich, Germany 
Microsoft Excel Microsoft Deutschland GmbH 
PerlPrimer version 1.1.14 http://perlprimer.sourceforge.net/ 
PubMed  http://www.ncbi.nlm.nih.gov/entrez 
SPSS 21.0 http://www-01.ibm.com/software/de/analytics/spss/ 
USCS Genome Browser http://www.genome.ucsc.edu 
 
 
   34 
4 Methods  
4.1 Patient samples collection 
4.1.1  Ethics and consent 
All the patients who underwent allogenic stem cell transplantation consented for 
the intestinal biopsies. Consent was taken prospectively by trained personnel. 
The project was approved by University Hospital Regensburg Ethics Committee 
(approval number: 09/059, Analyze der intestinalen GvHD 
Immundysregulkation bei der GvHD). All the investigation was conducted in 
accordance with the Helsinki Declaration.  
4.1.2 Clinical and Histological Information 
The overall clinical acute GvHD grade was diagnosed by clinicians according to 
NIH consensus. Histopathological grades were assessed by pathologist using 
standard criteria 120,121.  
4.1.3 Patient characteristics 
A total of 268 patients who were transplanted between July 2005 and November 
2014 were enrolled in this study. Serial biopsies were obtained from patients after 
allogenic stem cell transplantation either as a regular routine follow-up or when 
the potential GvHD was suspected. Following table lists the patient 
characteristics.  
 
Age at Tx (yr) Mean= 50.3  
SE= 12.6 
Median= 53.5  
Range= 16-71 
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Gender Male: n=172 patients 
Female: n= 96 patients 
Donor type Haploidentical: n= 5 
Siblings: n= 69 
Unrelated donor: n= 194 
Match  Identical: n= 213  
Haplo: n= 5 
Single or multiple allele/antigen 
mismatch: n= 50 
Conditioning  Standard: n= 37 
Reduced intensity: n= 231 
Stem cell source Double cord: n= 3 
Bone marrow: n= 16 
PBSC: n= 249 
Mean CD34/kg  5.47 +/- 1.6 CD34/kg 
Immunosuppressive prophylaxis CyA/MMF: n=55 
Post transplant Cyclo/Tacro/MMF: n=3 
CsA/MTX: n=210 
Unrelated donors: All additional 
serotherapy with ATG d-3—1 
Underlying disease stage Early: n=63 
Intermediate: n=97 
Advanced: n=109 
Diagnosis  AML: n= 144 
ALL: n= 29 
MDS: n= 22 
Myeloma: n=19 
Myeloproliferative neoplasia: n=19 
Lymphoma and Hodgkin´s disease: 
n=30 
Aplastic anemia n=5 
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GvHD after SCT None: n= 88 
Grade 1-2: n= 116 
Grade 3-4: n= 64 
 
4.2 Immunohistochemistry and Immunofluorescence 
More than seven decades ago, Coons and co-workers demonstrated for the first 
time fluorescence technique to detect corresponding antigens in frozen tissue 
sections122,123. However, only since early 1990s has this method (widely accepted 
as immunohistochemistry) being applied in surgical pathology. 
Immunohistochemistry (IHC) is a method for localizing specific antigens in tissues 
or cells based on antigen-antibody recognition and is used to exploit the 
specificity provided by the binding of an antibody with its antigen at a light-
microscopy level124. IHC allows the identification of cells with expression of 
specific surface markers in tissue. It also allows the assessment of the distribution 
and localization of specific cells in their surroundings and their relationship to 
other cells. Additionally, this method offers the possibility to observe the 
localization of specific molecules in the cells themselves.  
4.2.1 Sample collection and storage 
University Hospital Regensburg ethical review board approved the use of patient 
biopsies. All patients gave written informed consent in accordance with the 
Declaration of Helsinki. Gut biopsies were retrieved from ASCT patients by 
means of colonoscopy by trained physicians. Tissue biopsies were fixed in 4% 
formalin for 24 h and embedded in paraffin. Sections of approximately 2–3 µm 
thickness were cut from tissue blocks and stained with hematoxylin and eosin in 
accordance with the standard protocols. Histopathological analysis was 
performed without knowledge of the clinical data. Common histopathological 
features of GVHD, such as apoptosis of epithelium, loss of crypts and cellular 
infiltrates for neutrophils, eosinophils and lymphocytes in general, were assessed 
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separately for the epithelial area and the lamina propria. (Biopsies storage and 
handling took place in Institute of Pathology, University Hospital Regensburg) 
4.2.2 Immunohistochemistry 
Formalin fixed paraffin embedded (FFPE) biopsies were cut 2-3 µm thick, picked 
up on SuperFrost® Plus microscope slides. Slides were incubated at 80oC for 30 
minutes (this allows proper attachment of tissue section to the slides) to melt the 
paraffin and transferred to Xylol to dissolve the paraffin followed by descending 
alcohol line as follows: 
Step Length 
Xylol 5-10 min 
Xylol 5-10 min 
100 % Ethanol 3-5 min 
100 % Ethanol 3-5 min 
96 % Ethanol 3-5 min 
96 % Ethanol 3-5 min 
70 % Ethanol 3-5 min 
Distill water   
 
 Antigen retrieval was performed with citrate buffer (pH 7.2) for 32 minutes in 
microwave (300 Watts). Citrate buffer is widely known to break formalin cross 
links and unmask the antigens. Slides were fixed to the cover plates where biopsy 
section was sandwiched between the slide and the cover plate and were loaded 
into the cassette base. Sections were washed twice with 1x wash buffer (Dako, 
S300685-2 ), blocked with hydrogen peroxide (Dako, S2023) for 5 minutes to 
block endogenous peroxidase. Sections were then incubated with primary 
antibody prepared in antibody diluent (Dako, S2022) for 1 hour at room 
temperature (RT) with following antibodies: CD4, CD8, Foxp3, IL-17, IDO. Detail 
antibody information is provided in table 3.10.1. Secondary antibodies were used 
from Dako against the respective species. DAB substrate (Dako, K3468) was 
added for 10 minutes. Slides were gently taken out of cover plates. Cover plates 
were transferred to 0.3% sodium hypochlorite solution for cleaning. Slides were 
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the placed in hemalam for one minute and washed with warm tap water. Sections 
were placed in descending alcohol line as follows:  
Step Length 
70 % Ethanol 3-5 min 
96 % Ethanol 3-5 min 
96 % Ethanol 3-5 min 
100 % Ethanol 3-5 min 
100 % Ethanol 3-5 min 
Xylol 5-10 min 
Xylol 5-10 min 
  
Finally, biopsy sections were sealed with entellan (Merck, 1079610500) to finish 
the immunostaining bench work. Biopsies were manually analyzed at 400X 
magnification Zeiss Axioskop 40 microscope using semi quantitative scoring 
system. CD4, CD8 and IDO positive cell were analyzed in semi quantitative 
fashion. For Foxp3+ and IL-17+ cells, positive cells were counted in high power 
field (HPF). An HPF is defined as the 40X objective with the field diameter of 
0.31mm2. 4-10 HPF were analyzed depending on the size of biopsies. Semi 
quantitative scoring and HPF analysis was kindly performed by Senior Pathologist 
Dr. Elisabeth Huber.  
4.2.2.1 Preparation of citrate buffer 
Solution A: 2.1 g Citric acid monohydrate (C6H807-H2O, Merck,1002440500) in 
100 ml Millipore H2O (Storage at 4°C) 
Solution B: 29.41 g trisodium citrate dehydrate (C6H5Na3O7-2H20, Merck, 
1064480500) in 1 l Millipore H2O (Storage at 4°C) 
Preparation: 1 ml Solution A + 49 ml Solution B fill to 500 ml with Millipore H2O. 
Set pH to 7.2. (Storage at RT) 
4.2.2.2 Preparation of 1x wash buffer 
Working solution: 1: 10 dilution from concentrated 10X solution.  
100ml washing buffer 10x + 900ml Millipore H2O  
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4.2.2.3 Preparation of DAB substrate 
1 part DAB chromagen+49 parts DAB substrate diluent  
980µl DAB-Substrate + 20µl DAB-Chromogen, 100 µl per samples 
4.2.2.4 Preparation of 0,3% Sodium hypochlorite-Solution 
3 litre Solution: 200ml 4%-4,5% sodium hypochlorite + 2800ml distilled water 
Cleaning of cover plates: Cover plates were placed for 2 days in sodium 
hypochlorite, washed with distilled water and cleansed object slide surface with 
soap and sponge. Cover plates were then rinsed with distilled water and left to 
dry. Cleaning solution was stored in airtight box and changed every 6 months.  
4.2.3 Double Immunofluorescence 
FFPE biopsies were cut 4-5 µM thick. They were incubated at 80oC for 30 
minutes followed by immersing in Xylol twice for 10 minutes each following 
descending alcohol line as explained in paragraph 4.2.2. Sections were washed 
twice with PBS and blocked with 20% Bovine Serum Albumin (BSA) for 20 min at 
RT. Sections were washed twice with PBS. Double immunofluorescence staining 
was performed for Foxp3/CD4, Foxp3/CD8, IL-17/CD3, IL-17/CD4 and IL-
17/CD117. Primary antibodies diluted in 1% BSA were applied to sections for 45 
min at RT. Detailed information on primary antibodies is provided in table 3.10.1. 
Sections were washed twice with PBS. Primary antibodies were covalently linked 
to Alexa Flour 488 (dilution 1:75) or Alexa Flour 594 (dilution 1:150) for 30 
minutes at RT followed by two times washing with PBS. Detailed information on 
secondary antibodies is provided in table 3.10.1. Sections were counterstained 
with DAPI, washed twice with PBS and sealed with mounting media. Cells were 
manually counted at 400X magnification using Zeiss microscope.  
4.3 Quantitative Real-Time PCR  
Discovered by Kary Mullis in 1983 and awarded a Noble Prize in 1993 for his 
discovery, Polymerase Chain Reaction (PCR) is a method where a nucleic acid 
sequence can be exponentially amplified in vitro. PCR is one of the most powerful 
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technologies in molecular biology. With this technique, specific sequences within 
a DNA or cDNA template can be copied or ‘amplified’, many thousands to million-
fold using sequences specific oligonucleotides, heat stable DNA polymerase, and 
thermal cycling. PCR amplifies DNA exponentially, doubling the number of target 
molecules with each amplification cycle.  
4.3.1 Biopsies collection and storage 
Intestinal biopsies were collected after giving informed consent to patients who 
underwent allogenic stem cell transplantation in University Hospital Regensburg. 
Biopsies were transferred to 500 µl RNA later (Quiagen) and immediately stored 
at 4oC and were further stored at -20 oC. RNA was extracted when required.  
4.3.2 RNA extraction  
Before RNA extraction, tissues were centrifuged at 4000 rpm for 5 minutes and 
were transferred to 700 µl RLT buffer supplemented with 1% ß-mercaptoethanol. 
Tissues were then sonicated for five seconds, 3-5 times, till the complete 
homogenization was ensured. Tissues were filtered through QIAshredder column 
by centrifugation at RT for 3 min at 13000xg before proceeding to RNA extraction. 
Total RNA was extracted from intestinal biopsies using the RNeasy Mini Kit 
(QIAGEN) according to manufacturer’s recommendation. To remove potential 
DNA contaminations, on-column DNA digestion with the RNase-free DNase Set 
(Qiagen) was implemented according to the protocol. RNA concentration was 
measured with ND-1000 Nano Drop Spectrophotometer. RNA integrity and 
quality was controlled using Agilent Bioanalyzer as per manufacturer’s 
instructions. RNA was stored at -80 oC for further use.  
4.3.3 Reverse Transcription PCR (RT-qPCR) 
Total RNA was reverse transcribed into complementary DNA (cDNA) using 
Moloney murine leukemia virus reverse transcriptase (M-MLV RT) enzyme. 
Random decamers were used to prime cDNA synthesis. The volume of 1 μg of 
total RNA was adjusted to 13 μl with nuclease-free ddH2O and mixed with 1 μl 
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Random Decamers (Promega) and 1 μl dNTPs (10 mM) on ice. Secondary 
structures of RNA were dissolved by 5 min incubation in Thermocycler at 65 °C 
followed by immediate incubation ice for 1 min. After mixing with 4 μl M-MLV 
Buffer (5x;Promega), samples were incubated at 42 °C for 2 min. Reverse 
transcription started upon addition of 1 μl RT enzyme (50 min, 42 °C) and was 
stopped by heat inactivation of the enzyme (15 min, 70 °C). cDNA samples are 
stable at -20 °C.  
4.3.4 Quantitative Real-Time PCR (qPCR) 
 Reverse transcribed cDNA products were analyzed on a Mastercycler Ep 
Realplex using the QuantiFast SYBR Green PCR Kit. Primer sequences were 
purchased from Eurofins MWG Operon, Ebersberg, Germany except when other 
companies are mentioned. 18S was used as reference gene for all the gene of 
interest. PCR reaction was carried out in 96 well plate format adapted to the 
Eppendorf Realplex Mastercycler EpGradient S system. The amount of amplified 
DNA relative to reference gene18S rRNA was measured through the emission of 
light by SYBR green dye after each extension step. Melting curve was monitored 
to determine the specificity of amplification product. 
The reaction component and cycling protocol for RT-qPCR are listed below: 
 
Table 4.1: RT-qPCR reaction composition 
Components Concentration Volume 
SYBR Green mix (2x)  5 µl 
Nuclease-free ddH2O  3 µl 
Template DNA 1000 ng 1 µl 
Primer_sense 10 µM 0.5 µl 
Primer_antisense 10 µM 0.5 µl 
Final Volume  10 µl 
 
Table 4.2: Cycling protocol for RT-qPCR 
Cycle step Temperature Time consumed Number of cycles 
Initial denaturation 95°C 5 min 1x 
Denaturation 95°C 8 sec 
45x 
Annealing and Extension 58°C 20 sec 
Final denaturation 95°C 15 sec 
1x 
Final extension 60°C 15 sec 
Melting Curve 60-95°C 10 min 1x 
Cooling 4°C Hold  
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4.4 Fluidigm Array 
(These experiments were performed in Medical University of Göttingen and 
German Primate Centre, Göttingen, in October 2015 under Celleurope 
Secondment Scheme) 
Fluidigm array is a digital PCR that assists in quantification of expressed genes, 
like a RT-qPCR. It can run up to 9,216 reactions simultaneously where one can 
test 96 cDNA samples against 96 assays. The flexibility of fluidigm allows to 
design own reaction depending on one’s needs, letting run the samples in 
duplicates for higher accuracy.  
The individual reactions are carried out in a microarray chip, and are depicted on 
a computer as single squares forming a heat map; the color gradient is 
representative of the copy number of the DNA. The results are easy to interpret, 
visualize and to perform analysis on.  
This technique reduces pipetting errors, since the experiment is carried out in just 
few hours, consisting of a number of qPCR plates, and a lot more pipetting. In 
addition, a very small amount of cDNA is required for each reaction, which is very 
beneficial in instances where there are small amount of samples available, i.e. in 
the cases of human GvHD tissues. Figure 4.1 demonstrates a typical Integrated 
Fluid Circuit (IFC) Fluidigm plate with 96*96 dynamic array showing samples 
inlets and assay inlets. 
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Figure 4.1: 96*96 Dynamic Array IFC sample and assay inlets 
4.4.1 RNA isolation and cDNA synthesis 
RNA isolation and cDNA synthesis was performed in University Hospital 
Regensburg as described in section 4.3.2-4.3.3. Instead of 1000 ng RNA, only 
200 ng of RNA was synthesized to cDNA. The samples were parceled to Medical 
University of Göttingen in dry ice. Samples were received by corresponding 
collaborators within 24 hours and were safely stored untill further experiments 
were executed. 
4.4.2 Pre-amplification 
All the primers were obtained from Eurofins in a lyophilized state. Forward and 
reverse primers were reconstituted with nuclease free water to the concentration 
of 100µM. Equal volume of primers (5 µl each) was mixed to form a primer pair. 
Primer pairs were diluted to 500 nM (1:200 dilutions) using 1X DNA suspension 
buffer as shown in Table 4.3. So formed mixture is termed as Specific Target 
Amplification (STA) Primer Mix. This 10X STA Primer Mix was stored at 4 oC for 
short term use and at -20 oC for long term use. Experiment was performed for 48 
primer pairs in 96 samples at a time. For pre-amplification, STA reaction solution 
was prepared with TaqMan PreAmp Master Mix, 500 nM of pooled STA Primer 
Mix, DNA suspension buffer and cDNA as listed in Table 4.4.  
Table 4.3: Preparation of 500 nM (10X) pooled STA Primer Mix 
Component 48 Primer Pairs 
1 µl each primer pair (100 µM each) 48 µl 
1X DNA Suspension Buffer 152 µl 
Total 200 µl 
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Table 4.4: STA Reaction solution 
Component Volume/reaction (µl) 
96 samples with overage 
(µl) 
TaqMan PreAmp Master Mix (Applied 
Biosystem PN 4391128) 
2.5 260 
500 nM pooled STA Primer Mix 0.5 52 
DNA suspension Buffer 0.75 78 
cDNA 1.25  
Total 5.0 390 
 
In a 96 well plate, 3.75 µl of STA pre mix (pre amp master mix, STA primer mix 
and DNA suspension buffer) was pipetted as shown in table 2.5.2. To each well 
1.25µl of individual cDNA was added. At this point, the final concentration of STA 
mix was 50 nM. Plate was sealed using plate sealer and transferred to 
thermocycler for pre-amplification. 14 cycles were preamplified with the following 
thermal protocol: 95 oC for 10 min (reaction activation phase), 95 oC for 15 sec, 60 
oC for 4 min (amplification phase, 14 cycles), and 4 oC forever.  
In order to remove unincorporated primers in the preamplified samples, cleanup 
procedure was performed with Exonuclease I (E. coli derived enzyme). 
Exonuclease I was diluted to 4 Units/µl as shown in Table 4.5. 
 
Table 4.5: Exonuclease I Reaction solution 
Component Per 5 µl samples (µl) 96 Samples with Overage (µl) 
Water 1.4 166 
Exonuclease I Reaction Buffer 0.2 24 
Exonuclease I at 20 Units/µl 0.4 48 
Total Volume 2.0 240 
 
 
2 µl of Exo I at 4 Units/µl was added to each 5 µl STA reaction, vortexed, 
centrifuged and placed in a thermal cycler with the following programmer: 37 oC 
for 30 minutes (Digestion phase), 80 oC for 15 minutes (Inactivation phase) and 4 
oC for reaction termination. The final products were diluted 5-fold by adding 18 μl 
DNA suspension buffer, making a total cDNA volume of 25 μl. The cDNA was 
stored at -20 °C till further use.  
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4.4.3 Digital qPCR with Fluidigm 
 
Table 4.6: Preparing Sample Pre-Mix and Samples for Gene Expression 
using Fluidigm Dynamic Arrays 
Component Volume per inlet (μl) 
Volume per inlet 
with overage (μl) 
2X SsoFast EvaGreen Supermix with Low ROX 2.5 μl 3 μl 
20X DNA Binding Dye Sample Loading Reagent 0.25 μl 0.3 μl 
PreAmp and Exo I- treated sample 2.25 μl 2.7 μl 
Total Volume 5 μl  
3.3 μl of the Pre-Mix for each sample was aliquoted and mixed with 2.7 μl of the 
PreAmp and Exo I- treated cDNA on a 96 well plate. The plate was centrifuged 
and kept ready to be loaded onto the chip.  
  
Table 4.7: Preparing the Assay Mix 
Component Volume per inlet (μl) 
Volume per inlet 
with overage (μl) 
2X Assay Loading Reagent 2.5 μl 3 μl 
1X DNA Suspension Buffer 2.05 μl 2.46 μl 
100 μM each primer pair 0.45 μl 0.54 μl 
Total Volume 5 μl  
 
5.46 μl of the Assay Mix was aliquoted and mixed with 0.54 μl of each 100 μM 
primer pair mix, to make a total volume of 5 μl. The plate was centrifuged and 
kept ready to be loaded onto the chip.  
 
Priming and Loading the Dynamic Array IFC 
To prime the Dynamic Array chip prior to use, a control line fluid was injected into 
each accumulator on opposite sides of the chip. The blue protective film was 
removed from the bottom of the chip, and the chip was placed in an IFC 
Controller (MX for the 48.48 Dynamic Array or the HX for the 96.96 Dynamic 
Array) to be primed for the experiment. Following priming, 5 μl of each assay was 
loaded onto the left side of the chip, and 5 μl of each sample was loaded into the 
respective inlets on the right side of the chip. The Array was then returned to the 
respective IFC Controller to Mix the samples and assays onto the chip. The chip 
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was then run using the BioMark Gene Expression Data Collection software, 
following the given parameters for the 96.96 dynamic arrays.  
Table 4.8: Priming and Loading the Dynamic Array IFC 
Condition Temperature (°C) Time (s) 
Biomark HD Ramp 
Rate (°C) 
Biomark Ramp 
Rate (°C/s) 
Thermal Mix 70 2400 5.5 2 
 60 30 5.5 2 
Hot Start 95 60 5.5 2 
PCR* 96 5 5.5 2 
 60 20 5.5 2 
Melting Curve 60 3 1 1 
 60-95  1°C/3s 1°C/3s 
*40 cycles 
Genes that were analyzed by Fluidigm is given in material section 
4.5 Cell Culture 
4.5.1 Isolation of Monocytes  
Peripheral blood mononuclear cells (PB-MNCs) were separated by leukapheresis 
of healthy donors 125 , followed by density gradient centrifugation over 
Ficoll/Hypaque 126. Monocytes were then isolated from MNCs by counter current 
centrifugal elutriation 127. Elutriation was performed in a J6M-E centrifuge 
equipped with a JE 5.0 elutriation rotor and a 50 ml flow chamber (Beckman, 
Munich, Germany). After sterilizing the system with 6% H2O2 for 20 min, the 
system was washed with PBS. Following calibration at 2500 rpm and 4°C with 
Hanks BSS, MNCs were loaded at a flow rate of 52 ml/min. Fractions were 
collected and the flow through rate was sequentially increased according to Table 
4.9. Monocytes are the largest cells within MNCs and are thus mainly obtained in 
the last fraction. Monocyte yield were donor dependent, typically between 10-20% 
of total MNCs. Usually the purity of monocytes were 85-95%. Yield and purity 
varied slightly, depending on the donor. 
Table 4.9: Elutriation parameter and cell types 
Fraction Volume (ml) Flow rate (ml/min) Main cells isolated 
Ia 1000 52 Platelets  
Ib 1000 57 
B- and T- 
lymphocytes. NK cells 
IIa 1000 64 
IIb 500 74 
IIc 400 82 
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IId 400 92 
III 800 130 Monocytes  
 
4.5.2 Freezing and thawing of cells 
Freezing media consisted of 80% dimethyl-sulfoxide (DMSO) and 20% fetal calf 
serum (FCS). Cells were harvested and suspended in ice-cold RPMI 1640 and 1 
ml of cell suspension was added to 1 ml ice-cold freezing media in cryo-vials, 
properly closed and inverted twice to mix. To allow gradual freezing at a rate of -
1°C/min, the vials were placed in Styrofoam containers or isopropanol-filled cryo-
containers (Nalgene) and frozen at –80°C for 24 h. For long-term storage, the 
samples were then transferred to liquid nitrogen (-196°C).To recover frozen cells, 
the cell suspension was thawed in a room temperature at 25°C. To dilute the toxic 
DMSO, the suspension was transferred to 10-25 ml serum-containing media as 
soon as thawed and the cells were spun down (7 min, 300xg, 4°C) and 
resuspended in fresh media 
4.5.3 Dendritic cell culture 
Immature monocyte-derived dendritic cells (DCs) were generated by culturing 
0.67×106/ml elutriated monocytes in RPMI media supplemented with Glutamine, 
Penicillin/Streptomycin and 10% FCS. For monocytes to differentiate into 
immature DCs, 20 U/ml recombinant human IL-4 and 280 IU/ml GM-CSF was 
added as described earlier 128. Cells were incubated for 5 days at 37 oC with 5% 
carbon dioxide and 95% relative humidity. On day 5, immature DCs were treated 
with 100 ng/ml Lipopolysaccharide (LPS) without or with varying concentration of 
Indoxyl 3-Sulfate (I3S) (Sigma Aldrich). Cells were further incubated for 48 hours. 
I3S was added directly to monocytes as well on day 0 when mentioned. On day 
7, mature DCs were analyzed for cell viability and surface markers expression 
with flow cytometer and the cytokines in the supernatant was analyzed by ELISA.  
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4.5.4 Mixed Leukocyte Reaction  
When leukocytes from two unrelated individuals are cultured together, they begin 
to proliferate and the phenomenon is termed as mixed leukocyte reaction (MLR). 
First described in 1964, Mixed Leukocyte Reaction (MLR) could be useful as an 
indicator of compatibility between siblings prior to organ transplantation to assess 
the risk of rejection of the transplant129. Indeed, later on it could be shown that the 
observed proliferation of the T lymphocytes is a response to the "allogenicity" of 
the two leukocyte populations and that an MLR is absent if the mixed leukocyte 
culture (MLC) is carried out between syngeneic populations which express the 
same MHC alleles. In a syngeneic MLC, the proliferative response depends on 
the presence of both non-self-antigens and antigen presenting cells like dendritic 
cells in the leukocyte populations. In an allogeneic setting, the MHC 
incompatibility alone is sufficient to trigger T cell proliferation, the magnitude of 
the reaction being solely dependent on the costimulatory capacity of the antigen 
presenting cells. 
 
For MLR, ten thousand monocyte derived LPS stimulated mature DCs (with and 
without Indoxyl-3 sulfate) were co-cultured with hundred thousand lymphocytes 
(fraction IIa isolated by elutriation). Cells were cultured in 96 well plates with the 
final volume of 200 µl (100µl DCs+100 µl lymphocytes) in each well. The RPMI 
1640 media was supplemented with 5% filtered AB serum. Figure 4.2 depicts the 
diagrammatic experimental settings for MLR. DC donor and lymphocyte donor 
were chosen different to ensure allogenic reaction. Cells were incubated at 37 oC 
with 5% carbon dioxide and 95% relative humidity. On day 5, supernatant was 
collected from each condition from last 4 wells. On day 6, cells were counted and 
FACS was performed.  
 
 
 
Plate Layout for Mixed Lymphocyte Reaction. Shaded area represents each well.  
  1 2 3 4 5 6 7 8 9 10 11 12 
Lymphocytes alone A             
Lym+(DCs+LPS) B             
Lym+(DC+LPS+1µM IS) C             
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Lym+(DC+LPS+10µM IS) D             
Lym+(DC+LPS+100µM IS) E             
 F             
 G             
 H             
Figure 4.2: Plate Layout for Mixed Lymphocyte Reaction 
 
4.6 Fluorescence Activated Cell Sorting  
Multicellular organisms have identical DNA but varying amount of protein. 
Fluorescence activated cell sorting (FACS) is a flow cytometry based method that 
detect both intra- and extracellular protein of interest in/on the cells and sort them 
accordingly. Different proteins on a same cell can be marked with antibodies 
conjugated to different fluorochromes.  
The process begins with a population of single cells suspended in a medium, 
injected into a stable stream that forces cells to travel one by one in a laminar 
flow fashion. Cells pass through the beam of laser light. Scattered light and 
fluorescence emission provide information about the particle’s properties. Light 
scattered in forward direction provides information about size of cells and side 
scatter measures granularity of cells.  
Based on the excitation and emission wavelength of fluorochrome conjugated to 
cells, varying protein expression by cells can be measured. Also, using this 
fluorochrome labelled antibodies; different population of cells can be sorted and 
collected.  
To access the protein expression, 0.5 million of monocyte derived LPS-stimulated 
DCs   (see section 4.6.3) were collected on day 7 of the culture. Cells were 
washed twice with 1 ml FACS buffer. Cells were then stained with surface 
markers: CD1a, CD80, CD83, CD86 and HLA-DR along with the respective 
isotype control. Cells were incubated at 4 oC for 30 minutes. Cells were washed 
thrice with FACS buffer and resuspended in 300 µl FACS buffer. Flow cytometric 
measurement was performed on a BD FACS Calibur.  
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For lymphocytes, cells were incubated with CD4, CD8, CD25 and CD62L with 
their respective isotypes. For Foxp3, intracellular nuclear staining was performed 
according to the manufacturer’s instructions. Cells were incubated with 
fixation/permeabilization solution for 45 min at 4 oC. Cells were then washed 
thrice with permeabilization buffer. Foxp3 staining was performed for 30 min at 4 
oC. Cells were washed twice with permeabilization buffer and once with normal 
FACS buffer. Cells were resuspended in 300 µl FACS buffer and subjected to 
flow cytometry analysis.  
  
Composition of 
 FACS buffer: 5 ml of 60mg/ml Immunoglobulin + 5 ml of 10% sodium azide + 500 
ml PBS 
Fixation/Permeabilization solution: 1 part of Fix/Perm concentrate+4 part of 
Fix/Perm diluent 
Permeabilization buffer: 1 part of 10X buffer + 9 parts of distill water 
4.7 Enzyme Linked Immunosorbent Assay (ELISA) 
Supernatant from cell cultures were collected (day 7 for dendritic cells and day 5 
for lymphocytes) and were stored at -20 oC. Indirect or sandwich ELISA was 
performed to detect the cytokines released into cell culture medium. ELISA was 
performed according to manufacturer’s recommendation. The optical density of 
each well was immediately determined with a microplate reader set to 450 nm 
wavelength.  
4.8 Protein Analysis 
4.8.1 Protein Isolation 
For protein isolation, monocytes were isolated as described in section 4.5.1 and 
were cultured to immature DCs as described in section 4.5.3. Immature DCs were 
transferred to 6-well plates, stimulated with/without LPS and with/without Indoxyl 
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3-sulfate for 5 min, 30 min and 60 min. After respective stimulation, plates were 
transferred to ice, cells were transferred to 15 ml falcon tube (on ice), centrifuged 
at 1300 rpm for 7 minutes at 4 oC. Possible remaining cells in the 6-well plates 
were obtained by washing the wells with cold PBS for 3 times. 500 µl of freshly 
prepared pre-equilibration buffer (Buffer B) which contain Cytoplasmic Extraction 
Buffer (CEB) (also called Buffer A in this setting) was added to falcon tube 
containing stimulated DCs whereas 500 µl of buffer was added to 6-well plates to 
obtain any remaining cells in the plate. Cells were incubated in buffer for 4 min on 
ice and collected. Lysates was centrifuged and the supernatant was carefully 
discarded. Subsequently, 60 µl of freshly prepared lysis buffer (Buffer C) was 
added to the cell pellets and incubated for 10 min on ice. 60 µl of SDS buffer was 
added to the cell lysate and transferred to 95 oC heater for 10 min to denature the 
secondary protein structure. The obtained protein lysates were aliquoted in three 
Eppendorf tubes, 40 µl each, and stored at -80 oC for long term storage.  
Required Buffers and solutions 
Buffer A 
Table 4.10: Protein isolation Buffer A 
Reagents Final concentration Final volume 
Tris/HCl (pH 7,9 10mM 1 ml 
KCl 60mM 447 mg 
EDTA 1 mM 37 mg 
Distill Water  100 ml 
 
 
Buffer B 
 
Table 4.11: Protein isolation Buffer B 
Reagents Stock concentration Final concentration Final volume 
EDTA 500 mM 1.5 mM 3 µl 
Dithiothreitol 100 mM 1 mM 10 µl 
EGTA 200 mM 1 mM 5 µl 
ß- Glycerophosphate 1 M 50 mM 50 µl 
Sodium fluoride 1 M 50 Mm 50 µl 
Sodium pyrophosphate 250 mM 25 Mm 100 µl 
Sodium orthovanadate 200 mM 1 mM 5 µl 
Leupeptin 1 mg/ml 2 µg/ml 2 µl 
Pepstatin A 1 mg/ml 2 µg/ml 2 µl 
Aprotinine 2 mg/ml 2 µg/ml 1 µl 
Buffer A   772 µl 
Final volume   1000 µl 
 
 
 
Buffer C 
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Table 4.12: Protein isolation Buffer C 
Reagents Stock concentration Final concentration Final volume 
Nonidet P40 10% 0.4% 40 µl 
Chymostatin 20 mg/ml 100 μg/ml 5 µl 
Bestatin 5 mg/ml 10 μg/ml 2 µl 
E64 3 mg/ml 3 μg/ml 1 µl 
1,10-Phenanthrolin 0.1mg/ml 1 mM 1 µl 
Buffer B   951 µl 
Total end volume   1000 µl 
 
 
 
Table 4.13: Preparation of SDS sample buffer (2X) 
Reagents Final concentration Final volume 
Glycerine 20 % 10 ml 
Tris buffer (pH 6.8) 125 mM 5 ml 
Ssdium dodecyl sulfate 4 % 2 g 
2-Mercaptoethanol 10 % 5 ml 
Bromophenol Blue 0.02 % 10 mg 
 
 
 
 
4.8.2 SDS-Polyacrylamide-Gel Electrophoresis 
Protein samples obtained from section 4.8.1 were separated using discontinuous 
gel system which is composed of stacking gel and separating gel mainly 
consisting acrylamide (AA). Separating gel of 10% and stacking gel of 5% were 
prepared freshly as mentioned in Table 4.14. In order to achieve complete 
polymerization, ammonimum persulfate (APS) was added that acts as a free 
radical initiators and N, N, N’, N’-tetramethylenedianime (TEMED) was added to 
catalyze the gel polymerization as mentioned in Table 4.15.  
 
Table 4.14: SDS-PAGE stock solutions 
Gel stock solution Seperating  gel Stacking gel 
Final AA concentration 10% 5% 
Stacking gel buffer - 25 ml 
Separating gel buffer 25 ml - 
SDS (10%) 1 ml 1 ml 
Acrylamide (AA) (30%) 33 ml 16,7 ml 
Millipore water Adjust to 100 ml 
 
 
Table 4.15: SDS-PAGE gel mix solutions 
 Separating gel Stacking gel 
Separating gel stock solution 6 ml - 
Stacking gel stock solution - 2.5 ml 
TEMED 6 µl 2.5 µl 
APS (10%) 30 µl 20 µl 
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Two clean glass plates were held together congruent to each other by means of 
rubber seal in between glass plates to ensure leakage free space between the 
glasses. 6 ml of separating gel was casted in the glass plates, with isopropanol 
on top for quick polymerization. Once the separating gel polymerized, isopropanol 
was poured off and rinsed with distill water and let the glass dry. Stacking gel was 
poured over separating gel and the 10 well combs were gently inserted in the 
stacking gel avoiding air bubbles formation. Once the gel was polymerized, gel 
was mounted in the electrophoresis tank that was filled with 1X Laemmli buffer. 
The rubber seal was gently removed from between the plates; comb was gently 
taken out without damaging the gel. 10-20 µl of protein from section 4.8.1 was 
loaded into the separate wells, along with 5 µl of “Kaleidoscope precision plus 
protein standard” in a separate well.  The gel was run with 80 volts for the first 20 
minutes till the sample start running into the stacking gel. Voltage was increased 
to 100 volts for 30 min until the proteins reached the surface of separating gel. 
Next, the voltage was increase to 120 volts for almost 100-140 minutes and the 
separation of bands was continuously monitored until the desired proteins were 
resolved through the separating gel according to their size 130,131.  
Table 4.16: Required buffers and solutions for SDS gel preparation 
Solutions Final concentration Weight Constituents 
Separating gel buffer 1.5 M 90.83 g Tris/HCl pH 8.8 
 
Add Millipore water to 500 ml 
 
Stacking gel buffer 0.5 M 30 g Tris/HCl pH 6.8 
 
Add Millipore water to 500 ml 
 
Sodium dodecyl sulfate 10% 10 g SDS 
 
Add Millipore water to 100 ml 
 
Ammonium persulfate 10% 1 g APS 
 
Add Millipore water to 10 ml and store aliquots at -20
o
C 
 
Laemmli buffer (5X) 40 mM 15 g Tris 
 0.95 M 21 g Glycine 
 0.5% 15 g SDS 
 Add Millipore water to 3 liters, store at RT 
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4.8.3 Western Blot analysis and Immunostaining 
Proteins separated by SDS-PAGE were electrophoretically blotted onto the PVDF 
(Polyvinyl difluoride) membrane using a three-buffer semi-dry system and then 
visualized using specific antibodies immunostaining and the ECL detection kit. 
To transfer the proteins from the gel to the membrane, PVDF membrane was cut 
into the size of gel. Membrane was first soaked in 70% isopropanol and 
transferred to anode buffer B. Meanwhile, three pieces of whatman filter paper, 
cut in the size of membrane, were soaked in anode buffer A, and placed on the 
electrophoresis chamber. Three more whatman papers were soaked in anode 
buffer B, placed on top of first three papers. Air bubbles were gently removed 
from the papers. With the help of forceps, membrane was placed over the filter 
paper. SDS gel was carefully removed from glass plate, immersed in buffer B for 
10 s and placed on top of the membrane. Another 3 sheets of whatman soaked in 
buffer C were laid on top of the gel, followed by the cathode. Protein transfer took 
place 11 volts for 1 hour at RT.  
Table 4.17: Required buffers and materials for transferring protein for 
immunodetection 
Buffer A  (Anode) 36.3 g (300 mM) Tris (pH 10.4) 
 200 ml (20%) Methanol 
 Add Millipore water to 1000 ml 
 
Buffer B (Anode) 3.03 g (25mM) Tris (pH 10.4) 
 200 ml (20%) Methanol 
 Add Millipore to 1 liter 
 
Buffer C  (Cathode) 5.2 g (4mM) ε-amino-n-caproic acid pH 
7.6 
 200 ml (20%) Methanol 
 Add Millipore water to 1 liter 
 
Polyvinyl difluoride 
membrane 
Cut to a size of SDS gel 
 
PVDF membrane onto which proteins were blotted was washed 3 times, 10 min 
each in wash buffer (1X TBS + 0.1% Tween 20) and blocked with 5% milk (5 g 
milk dissolved in wash buffer and filtered) for 1 hour at RT.  Membrane was 
washed once again 3 times, 10 min each with wash buffer, incubated with primary 
antibody (diluted in 5% milk) overnight at 4 oC. Next day, membrane was washed 
three times, incubated with horseradish peroxidase (HRP)-conjugated secondary 
antibody (diluted with 5% milk) for 1 hr. at RT. For detection of the protein bands, 
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membrane was washed 3x10 min followed by swirling in 5 ml ECL reagent (+ 1.5 
µl of 30% hydrogen peroxide) for 2 minutes. Blots were exposed to high 
performance chemiluminiscence film for 5-300 seconds depending on the signal 
intensity.  
All the protein of interest were always normalized to the reference gene, beta-
actin. For this, previous antibody was stripped off. For this, membrane was 
washed 3x10 min followed by stripping off the old signal with Reblot solution (1:10 
diuluted) for 15 min at RT. Membrane was washed 3x10 min and preceded with 
blocking, washing, primary and secondary antibody procedure. Stripping was 
performed every time when more than one antibody was to be bound on the 
same membrane and these antibodies are isolated from the same species.  
Images were processed, analyzed and graphed using Image Lab software.  
 
4.9 Statistical Analysis 
SPSS was used for patient data analysis. Data was analyzed for normal 
distribution. Normally distributed data were analyzed by student t test for two 
groups and one way anova for more than two groups. Non normally distributed 
data were analyzed by Mann Whitney test for two groups and Kruskal Wallis test 
for more than two groups. Correlations were depicted with Pearson correlation 
test for normally distribued data and Spearman correlation for non normal data. 
Experiments involving healthy volunteers were analyzed with graphpad prism. 
Non parametric one way anova was performed to calculate statistical 
significance. 
For the entire experiments, graph represents mean and standard error of mean 
(s.e.m). Null hypothesis (no difference between two or more groups) was 
assumed for all the graphs. p values less than 0.05 between two or more groups 
was considered to reject null hypothesis thus being statistically significant. 
Data transformation or normalization was not performed throughout the 
experiment thus all the results are the representation of raw data.  
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5 Results 
5.1 Analysis of immune cell infiltrates during acute gastro-
intestinal (GI) graft-versus-host disease (GvHD).  
5.1.1 Analysis of CD4+ cell infiltrates and CD8+ cell infiltrates during 
acute GI-GvHD 
GvHD is described by the activation of donor T cells in the recipient’s 
hematopoietic system 1. CD4+ T cells and CD8+ T cells play an essential role in 
GvHD as they represents the T lymphocytes of immune system. CD4+ T cells and 
CD8+ T cells were analyzed in the gut biopsies of patients after ASCT. Formalin 
fixed paraffin embedded (FFPE) gut biopsies were stained with a monoclonal 
anti-CD4 antibody (undiluted) and a monoclonal anti-CD8 antibody (1:2 dilution). 
Positive cells were analyzed in Zeiss Axioscope 40 microscope. Since T cells 
represents the majority of immune cell infiltrates, counting CD4+ and CD8+ T cells 
manually was not feasible. Therefore the biopsies were scored in a semi 
quantitative fashion 132 (this was done in close collaboration with Dr. Elisabeth 
Huber , Institute of Pathology, University Hospital Regensburg). Scored values 
were collected and analyzed using SPSS. Patients were divided into three 
groups: i) with no GvHD, ii) mild GvHD as grade 1, and iii) moderate to severe 
GvHD as grade 2-4. Upon analysis, the number of infiltrating CD4+ T cells 
showed increasing trend in gut biopsies of the patients who were diagnosed with 
grade 1 GvHD. Patients who were diagnosed with grade 2-4 GvHD did not show 
any difference in CD4+ T cell infiltrates when compared to non GvHD controls, 
they rather had less CD4+ T cells infiltration when compared to grade 1 GvHD as 
shown in Figure 5.1(A). On the contrary CD8+ T cells were significantly increased 
along with the exacerbation of GvHD as shown in Figure 5.1(B) suggesting that 
CD8+ T cell mediated inflammation occurs during the course of GvHD.  
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Figure 5.1: Infiltration of CD4+ T cells and CD8+ T cells in gut during acute 
GI-GvHD 
A. Infiltration of CD4+ T cells shows increasing trend during grade 1 GvHD which 
declines during grade 2-4 GvHD to the level of non GvHD patients. N=199 (No 
GvHD=81; Grade 1=64; Grade 2-4=54). B. CD8+ T cell infiltrates significantly 
increases in grade 1 GvHD and even stronger in grade 2-4 GvHD when 
compared to non GvHD controls. N=197 (No GvHD=81; Grade 1=61; Grade 2-
4=55). The distribution of CD4+ and CD8+ T cells were non-normal therefore non-
parametric Kruskal-Wallis test was performed to calculate p values. Bar 
represents mean ± s.e.m. 
 
 
Next, the numbers of infiltrating CD4+ T cells were correlated with infiltration of 
CD8+ T cells, absence of crypts and apoptosis of epithelial cells in gut biopsies. 
CD8+ T cells were also correlated with crypt loss and epithelial apoptosis.  
 
As shown in Table 5.1, CD4+ T cell infiltrates highly correlated with the numbers 
of infiltrating CD8+ T cells confirming the fact that CD4+ T cells are necessary for 
the maintenance of CD8+ T cells133,134. CD4+ T cells did not correlate with crypt 
loss but were associated with apoptosis of epithelial cells in the gut which could 
be attributed to different CD4 subsets like Th1, Th2 and Th17 cell type leading to 
CD8+ T cell activation. CD8+ T cells highly correlated with CD4+ T cell infiltrates 
loss of crypts and epithelial apoptosis, thus supporting the fact that increased 
infiltrations of cytotoxic T cells destroy crypts and epithelia and hence 
exacerbates GvHD (Figure 5.1 B). Furthermore, Kaplan-meier estimates revealed 
that patients with greater degree of epithelial apoptosis has significantly higher 
frequency of TRM when compared to the patients with lesser epithelial apoptosis 
confirming that apoptosis is the diagnostic hallmark of GvHD. 
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Table 5.1: Correlation table of CD4+ and CD8+ infiltrates with crypt loss and 
epithelial apoptosis in the gut of ASCT patients 
Nonparametric Spearman’s correlation was used to determine the correlation 
coefficient and significance between each group.  
  CD4
+
 cells CD8
+
 cells Crypt loss Epithelial 
apoptosis 
CD4
+
 
cells 
Correlation 
coefficient 
 0.329 -0.06 0.145 
Number of 
patients 
 197 200 200 
P value  <0.001 0.35 0.04 
CD8
+
 
cells 
Correlation 
coefficient 
0.329  0.31 0.225 
Number of 
patients 
197  198 198 
P value <0.001  0.001 <0.001 
 
 
 
Figure 5.2: Survival curve in relation to epithelial apoptosis. 
Cumulative TRM significantly increases (p log rank= 0.001) in patients with 
greater degree of epithelial apoptosis when compared with patients with less 
epithelial apoptosis. N= 109 patients.  
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5.1.2 Foxp3+ cells increase during acute GI-GvHD and are produced 
by CD4+ cells and/or CD8+ cells 
Single antibody immunohistochemistry for Foxp3 was performed on 199 gut 
biopsies as explained in method section 4.2.2. Foxp3+ cells were determined by 
the strong nuclear staining with the morphology that resembles lymphocytes. 
Manual counting of Foxp3+ cells in gut biopsies revealed that these cells 
significantly increases in the  patients suffering from severe acute GI-GvHD when 
compared to non GvHD patients as shown in Figure 5.3(A), which is a 
controversial finding to the existing belief that Tregs are diminishing during 
GvHD135. Grade 1 GvHD patients also depicted increasing trend of Foxp3+ T cell 
infiltrates compared to non GvHD patients. To confirm the upregulation of Tregs 
during GvHD, FOXP3 mRNA was analyzed by RT-qPCR as described in method 
section 4.3. This analysis revealed that FOXP3 expression significantly increases 
during severe acute GI-GvHD when compared to non GvHD controls. 
Upregulation of FOXP3 mRNA expression between non GvHD patients and 
grade 1 GvHD patients; and between grade 1 vs grade 2-4 patients were also 
nearly significant (0.07 and 0.06 respectively) as shown in Figure 5.3(B). Taken 
together, a significant increase of Tregs during GvHD suggests a previously 
unrecognized immunoregulatory loop that might have been induced due to 
pronounced inflammatory reaction mediated by effector T cells.  
 
 
Figure 5.3: Infiltration of Foxp3+ cells and expression of FOXP3 mRNA in GI 
tract during acute GI-GvHD. 
A. Foxp3+ cells significantly upregulates during moderate-severe GI-GvHD 
compared to non GvHD patients. N=199 (No GvHD=80; Grade 1=64; Grade 2-
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4=55). B. FOXP3 mRNA significantly upregulates during moderate-severe GvHD 
when compared to non GvHD controls. N=314 (No GvHD=147; Grade 1=94; 
Grade 2-4=73). Data were non-normally distributed therefore non-parametric 
Kruskal-Wallis test was performed to calculate p values. Bar represents mean ± 
s.e.m. 
 
In order to verify these results obtained in analyzing FOXP3 expression on mRNA 
level, the correlation with Foxp3 protein expression was analyzed for 88 gut 
biopsies. The result demonstrated that Foxp3 protein expression highly correlates 
with FOXP3 mRNA expression as shown in Table 5.2.  
 
 
Table 5.2: Correlation table of Foxp3+ cell infiltrates and FOXP3 mRNA in 
the gut of ASCT patients. 
Nonparametric Spearman’s correlation was used to determine the correlation 
coefficient and significance between protein and mRNA expression.  
 FOXP3 mRNA 
Foxp3
+
 infiltrates  
Correlation coefficient 0.686 
Significance < 0.001 
No. of patients 88 
.  
 
Subsequent interest was to explain the possible cellular source of Foxp3+ cells for 
which single and double immunofluorescence techniques were established. 
Single staining for Foxp3 expression was successfully established using anti-
Foxp3 antibody as shown in Figure 5.4 B. As indicated by withe arrow, positive 
cells were determined nuclear Foxp3 staining. The specificity of antibody was 
determined by using negative control as shown in Figure 5.4 A. Likewise, single 
staining using an anti- CD4 antibody was established as shown in  
Figure 5.5.  
Figure 5.5 A is a negative control where only secondary antibody was used in 
absence of primary antibody. No positive signals were observed.  
Figure 5.5 B is a positive control for anti-CD4 antibody where both primary and 
secondary antibodies were used. It can be seen that thymus tissue contains 
numerous CD4+ T cells and therefore served as a positive control for CD4 signal 
in subsequent experiments. 
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Figure 5.4: Foxp3 staining in thymus tissue.  
A. Negative control without primary antibody, only with secondary antibody. B. 
Positive control with anti-Foxp3 primary antibody. Secondary antibody recognizes 
the first antibody and is labelled with Alexa Flour 488. White arrows indicates 
Foxp3+ cells. Nuclei were counterstained with DAPI (blue). Images were taken at 
400 times magnification. Scale bar represents 20 µm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: CD4 staining in the thymus tissue.  
A. Negative control without primary antibody, only with secondary antibody. B. 
Positive control with anti-CD4 primary antibody. Secondary antibody recognizes 
the first antibody and is labelled with Alexa Flour 594. Numerous CD4+ cells are 
seen in red. Nuclei were counterstained with DAPI (blue). Images were taken at 
400 times magnification. Scale bar represents 20 µm. 
 
After the successful establishment of single stainings for Foxp3 and CD4, the 
next step was to establish double staining. In order to establish the successful 
double immunofluorescence method, thymus tissue was labelled with Foxp3 and 
CD4 together. Primary antibodies that were raised in different species (Foxp3 in 
A B 
A B 
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mouse and CD4 in rabbit) were mixed together, thymus tissue was stained with 
primary antibodies followed by specific secondary antibodies. Image analysis was 
done by using an epifluorescence microscope. Pictures were taken at 400 times 
magnification with the desired filters. Figure 5.6 represents an exemplary double 
immunofluorescence.  
 
Figure 5.6: Foxp3+CD4+ double staining of thymus tissue.  
Foxp3 signal corresponds to Alexa Flour 488 (green). CD4 signal corresponds to 
Alexa Flour 594 (red). Overlay is a merge of all channels where arrow indicates 
double positive cells. Nuclei were counterstained with DAPI (blue). Images were 
taken at 400 times magnification. Scale bar represents 20 µm. 
 
Once the double fluorescence methodology was well established, the method 
was applied on colon biopsies of transplanted patients. Double 
immunofluorescence was performed with the combination of anti-Foxp3 and anti-
CD4 antibodies in 22 transplanted colon biopsies. As shown in Figure 5.7, Foxp3+ 
cells were positive for CD4 marker in ASCT patients. Foxp3 positive cells are 
well-known to express the CD4 marker as an indicator of CD4+ T cells. 
Interestingly it was observed that there exist some Foxp3+ cells which are 
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negative for CD4 marker as shown in Figure 5.8. Therefore double staining for 
Foxp3 and CD8 was performed to further characterize the Foxp3 positive, CD4 
negative cell population.  
 
 
Figure 5.7: Foxp3+CD4+ double staining of colon tissue of GvHD patient.  
Foxp3 signal corresponds to Alexa Flour 488 (green) shown by green arrow. CD4 
signal corresponds to Alexa Flour 594 (red) shown by red arrow. Overlay is a 
merge of all channels where white arrow indicates double positive cells. Nuclei 
were counterstained with DAPI (blue). Images were taken at 400 times 
magnification. Scale bar represents 20 µm. 
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Figure 5.8: Foxp3+CD4+ double staining of colon tissue of GvHD patient. 
Foxp3 signal corresponds to Alexa Flour 488 (green). CD4 signal corresponds to 
Alexa Flour 594 (red). Image is a merge of three channels where white arrow 
indicates double positive cell. Yellow arrow indicates CD4-Foxp3+ cells. Nuclei 
were counterstained with DAPI (blue). Image was taken at 400 times 
magnification. Scale bar represents 20 µm. 
 
 
Anti-CD8 staining was established in similar way to the anti-CD4 staining. Double 
staining was performed for Foxp3+CD8 on 22 colon biopsies of ASCT patients. 
Surprisingly CD8+ Foxp3+ cells were observed in the colon of GvHD patients as 
shown in Figure 5.9. Therefore it was evident that not only CD4+ T cell but also 
CD8+ T cells are involved in Foxp3 expression. These results suggest the 
involvement of at least two different subsets of regulatory T cells in GvHD that 
might be involved in dampening the inflammatory reaction and establishing 
immune homeostasis in the course of GvHD. 
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Figure 5.9: Foxp3+CD8+ double staining of colon tissue of GvHD patient. 
Foxp3 signal corresponds to Alexa Flour 488 (green) shown by green arrow. CD8 
signal corresponds to Alexa Flour 594 (red) shown by red arrow. Overlay is a 
merge of all channels where white arrow indicates double positive cells. Nuclei 
were counterstained with DAPI (blue). Images were taken at 400 times 
magnification. Scale bar represents 20 µm. 
 
After realizing the existence of two types of Foxp3+ cells i.e. CD4+ and CD8+ 
Foxp3+ cells, the number of double positive cell per high power field was 
determined. Both sets of double positive cells (CD4+Foxp3 and CD8+Foxp3) 
were manually counted per high power field. Depending on the size of biopsies, 
4-10 high power fields were analyzed. As shown in Figure 5.10 (A) CD4+ Foxp3+ 
cells were significantly upregulated in patients with Grade 1 GvHD when 
compared to non GvHD patients. Grade 2-4 GvHD patients exhibited upregulating 
trend as compared to non GvHD patients. Of note, CD8+ Foxp3+ cells seemed to 
upreulated only in grade 2-4 GvHD patients as shown in Figure 5.10 (B). The 
importance of CD8+ Foxp3+ cells in GvHD mediated protection has been well 
documented in experimental model 136 but so far no evidence exists in clinical 
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data. It can be suspected that these CD8+Foxp3+ cells are induced in later phase 
of GvHD possibly to counterbalance the extreme immune mediated inflammation.  
 
Figure 5.10: Quantification of CD4+Foxp3+ cells and CD8+Foxp3+ cells by 
double immunofluorescence. 
A. Number of Foxp3+ cells/HPF that are produced by CD4+ T cells. Double 
positive cells significantly increases in patients during grade 1 GvHD and has 
increasing trend in grade 2-4 GvHD. B. Number of Foxp3+ cells/HPF that are 
produced by CD8+ T cells. There is a trend of strong upregulation in the patients 
in Grade 2-4 GvHD. N=22 patients. Non-parametric Kruskal-Wallis test was 
performed to calculate p value. Bar represents mean ± s.e.m. 
 
5.1.3 IDO+ cells increase during acute-GI-GvHD and correlates with 
Foxp3 expression 
 
Indoleamine 2,3-dioxygenase (IDO) is an intracellular enzyme that degrades the 
essential amino acid tryptophan 137. IDO suppresses T-cell responses and 
promotes immune tolerance. Its immunosuppressive properties have been 
implicated in mammalian pregnancy, tumor resistance, chronic infection, 
autoimmunity and allergic inflammation138. Single antibody immunohistochemistry 
was performed on 193 gut biopsies to analyze IDO expression after allogenic 
stem cell transplantation. Unbiased semi quantitative scoring was performed on 
stained biopsies (by Dr. Elisabeth Huber in co-operation with department of 
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pathology). IDO+ cells significantly increased in patients showing the symptoms of 
low, medium or high grade GvHD when compared to GvHD free patients as 
shown in Figure 5.11(A). Furthmore, IDO mRNA was analyzed by RT-qPCR in 
190 samples. Upregulation of IDO expression during GvHD at protein level was 
further supported by increased expression of IDO mRNA at transcriptional level 
as shown in Figure 5.11(B). In addition, correlation was calculated for IDO protein 
and mRNA expression as shown in Table 5.3 and was observed that gene and 
protein expression highly correlates with each other. Moreover, expression of IDO 
was correlated with Foxp3 protein and FOXP3 mRNA expression. It was 
interesting to note that IDO protein highly correlates with Foxp3 protein and 
FOXP3 mRNA expression (table 5.4). IDO1 mRNA as well highly correlated with 
Foxp3 protein and FOXP3 mRNA expression. These findings reveal the existence 
of strong immunoregulatory loop between IDO expression and Foxp3 expression 
in response to GvHD-mediated inflammation in  ASCT patients. To our surprise, 
neutrophil infiltrates were also found to be significantly correlated with IDO and 
Foxp3 expression both at protein and mRNA level. This raises the hypothesis that 
myeloid derived suppressor cells are invoved in immunoregulation during GvHD. 
As myeloid derived suppressor cells are dependent on an intact and diverse 
microbiome, it will be of interest to assess the interaction of microbiota disruption 
with intestinal immunoregulation in the future. An intact microbiome might help to 
compensate inflammation by allowing induction of regulatory mechansims.  
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Figure 5.11: Infiltration of IDO+ cells and expression of IDO1 mRNA in GI 
tract during acute GI-GvHD. 
A. IDO+ cells significantly upregulates during GvHD compared to non GvHD 
controls. N=193 (No GvHD=80; Grade 1=60; Grade 2-4=53). B. IDO1 mRNA 
significantly upregulates during severe GvHD when compared to non GvHD 
controls. N=190 (No GvHD=100; Grade 1=52; Grade 2-4=38). Data were non-
normally distributed therefore non-parametric Kruskal-Wallis test was performed 
to calculate p values. Bar represents mean ± s.e.m. 
 
 
Table 5.3: Correlation table of IDO with Foxp3 (protein and mRNA) infiltrates 
and neutrophil infiltrates.  
Nonparametric Spearman’s correlation was used to determine the correlation 
coefficient and significance between protein and mRNA expression. Lp=lamina 
propria 
  IDO 
protein 
IDO1 
mRNA 
Foxp3 
protein 
FOXP3 
mRNA 
Neutrophils 
in Lp 
IDO 
protein 
Correlation 
coefficient 
1 0.275 0.381 0.425 0.486 
Number of 
patients 
194 75 193 87 194 
P value  0.01 <0.001 <0.001 <0.001 
IDO1 Correlation 
coefficient 
0.275 1 0.476 0.221 0.525 
   69 
mRNA Number of 
patients 
75 191 75 189 77 
P value 0.01  <0.001 0.002 <0.001 
Neutrophils 
in Lp 
Correlation 
coefficient 
0.486 0.525 0.456 0.567 1 
Number of 
patients 
194 77 200 90 206 
P value <0.001 <0.001 <0.001 <0.001  
 
5.1.4 IL-17+ cells decrease during acute GI-GvHD and are produced 
by non-T cells 
IL-17 cytokine is long known to be hallmark of Th17 cell type while only recently 
researchers revealed that the majority of IL-17 released during an inflammatory 
response is produced by innate immune cells 109. To analyze the cellular 
expression of IL-17+ cells after ASCT, immunohistochemistry was performed on 
197 gut samples after ASCT. It was observed that IL-17 significantly 
downregulates as GvHD exacerbates (Figure 5.12 A). To further confirm the 
downregulation of IL-17 in ASCT patients, the transcription factor for IL-17, RORC 
was analyzed at mRNA level using RT-qPCR on 197 transplanted biopsies. In 
parallel to protein expression, RORC mRNA expression was also downregulated 
with the severity of GvHD (Figure 5.12 B) supporting the hypothesis that these IL-
17+ cells could be protective rather than inflammatory in the context of ASCT and 
that the loss of these protective cells could contribute to potential GvHD.  
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Figure 5.12: Infiltration of IL-17+ cells and expression of RORC mRNA in GI 
tract during acute GI-GvHD. 
A. IL-17+ cells significantly downregulates during GvHD compared to non GvHD 
controls. N=197 (No GvHD=79; Grade 1=63; Grade 2-4=55). B. RORC mRNA 
significantly downregulates during severe GvHD when compared to non GvHD 
controls. N=197 (No GvHD=100; Grade 1=57; Grade 2-4=40). Data were non-
normally distributed therefore non-parametric Kruskal-Wallis test was performed 
to calculate p values. Bar represents ± s.e.m. 
 
The correlation between IL-17 protein and RORC mRNA was analyzed for 82 gut 
biopsies that were common samples for IHC and RT-qPCR. Significant 
correlation was observed between protein expression and gene expression when 
data were correlated in terms of GvHD grade 0,1 and 2-4 as shown in Figure 5.13 
(A). The loss of IL-17 and RORC was analyzed in terms of transplant related 
mortality(TRM). 82 patients enrolled in the study showed that the loss of IL-
17/RORC potentially leads to significantly higher TRM as shown in Figure 5.13 
(B). Taken together, these results suggests that there is a potential loss of 
protective IL-17+ cells during GvHD which leads to higher transplant related 
mortality.  
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Figure 5.13: IL-17 protein correlates with RORC mRNA and Treatment 
Related Mortality (TRM) occurs more frequently in patients with low IL-
17/RORC expression. 
A. Scatter plot diagram of IL-17 expression and RORC expression with the 
correlation coefficient of 0.224 and p value 0.04 when data were controlled for 
histological GvHD. N=82 patients. B. Green circles represent patients with 
Relapse Related Mortality (RRM) or survival. Red circles represent patients with 
Transplant related mortality(TRM). Patients with reduced IL-17/RORC expression 
exhibited frequent TRM with the correlation coefficient of 0.297 and p value 0.006 
when data were controlled for TRM.  
 
IL-17 is a typical marker for Th-17 cell types which are inflammatory subset of 
CD4+ T cells 139,140. Along with the downregulation of IL-17 and the hypothesis 
that IL-17+ cells are protective, next, the cellular source of IL-17 was analyzed. 
Double immunofluorescence was established for IL-17 and CD4 to depict if these 
IL-17 cells are of Th-17 origin or not. For this, colon biopsies of Crohn’s disease 
patients were utilized to establish single staining for IL-17 and CD4 individually as 
shown in Figure 5.14. Anti-CD4 antibody was used in undiluted state as 
mentioned before. The anti-IL-17 antibody was titrated in different dilution. Based 
on precise signal that can be well differentiated from background, dilution of 1:25 
was chosen for the consecutive experiments. Due to the complexity of 
immunofluorescence for cytokines on paraffin biopsies, it was necessary to 
assure that the specific signal is being analyzed and that false signal, or 
background, or autofluorescence is being avoided. Therefore two individual 
analyzers (one analyzer being highly experienced pathologist) manually counted 
IL-17+ cells per high power filed on 39 colon biopsies in a blindfold fashion at 40X 
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magnification. As shown in Figure 5.15, two individual analyzers observed similar 
results. Total IL-17+ cells were downregulated with an exacerbation of GvHD. The 
number of cells counted per high power field was also similar.  
 
Figure 5.14: IL-17 and CD4 staining in colon tissue. 
A. IL-17 signal corresponds to AF 488 shown by green arrows. B. CD4 signal 
corresponds to AF 594 shown by white arrows. Numerous CD4+ cells are seen in 
red. Nuclei were counterstained with DAPI (blue). Images were taken at 400 
times magnification. Scale bar represents 20 µm. 
 
 
Figure 5.15: IL-17+ cells analysis by two independent analyzers. 
Two analyzer individually analyzed colon biopsies after ASCT. Both analyzers 
showed downregulation of IL-17+ cells at the course of GvHD. Anti-IL-17 antibody 
was applied on biopsies followed by Alexa Flour 488 conjugated secondary 
antibody. IL-17+ cells were manually counted per high power field by two 
analyzers with epifluorescence microscope in a blindfold fashion. Number of 
samples included in analyzes is 39 for analyzer 1 and 33 for analyzer 2. Data 
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were non-normally distributed therefore non-parametric Kruskal-Wallis test was 
performed to calculate p values. Bar represents mean + s.e.m. 
 
After successful establishment of single immunofluorescence, and the 
confirmation that the protein of interest, IL-17 staining is trustworthy, double 
immunofluorescence was established as shown in Figure 5.16 where double 
positive cell (IL-17+CD4+) and IL-17 positive but CD4 negative cell can be seen.  
. 
 
Figure 5.16: Establishment of IL-17+CD4+ double staining in colon biopsy of 
Crohn‘s disease patient. 
A. Green arrow indicates IL-17+ cell. Red arrow indicates CD4+ cell. Several CD4+ 
cells can be seen in lamina propria of colon. Overlay image shows double 
positive cell indicated by white arrow. B. Green arrow represents IL-17+ cell. 
Several CD4+ cells can be seen in lamina propria of colon. Overlay shows CD4-
IL-17+ cell indicated by yellow arrow. Nuclei were counterstained with DAPI 
(blue). Images were taken at 400 times magnification. Scale bar represents 20 
µm. 
 
 
Once the double immunofluorescence was well established, the technique was 
applied on colon biopsies of allogenic stem cell transplant patients. At 400 times 
magnification per high power field, we aimed to analyze and quantify double 
positive cells. Surprisingly, IL-17 signal did not colocalize with CD4 signal in all 
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the samples tested as shown in Figure 5.17 (A). To our knowledge this is the first 
report to reveal the existence of non CD4 IL-17+ cells in human gut biopsies 
therefore supporting the idea that non Th17 cells are able to produce IL-17. 
However, other T cells like gammadelta T cells and NKT cells are possibly a 
major source of IL-17. To further clarify the cellular source of IL-17, double 
immunofluorescence was performed for IL-17 and CD3 together. 39 transplanted 
colon biopsies were stained for IL-17 and CD3. Again, to our surprise, so far none 
of the IL-17 signal colocalized with CD3 expression so far tested as shown in 
Figure 5.17 (B) suggesting a new paradigm in the role of IL-17 in GvHD. We 
assume that these IL-17+ cells are of innate origin and are perhaps of protective 
nature in the context of GvHD related inflammation 
 
Figure 5.17: IL-17+CD4+ (A) and IL-17+CD3+ (B) double staining of colon 
tissue of ASCT patient. 
A. Green arrow indicates IL-17+ cells. Red arrow indicates CD4+ cells. Several IL-
17+ and CD4+ cells can be seen in crypts and lamina propria of colon. Overlay 
image shows that IL-17 signal do not colocalize with CD4 signal. B. Green arrow 
represents IL-17+ cells. Red arrow indicates CD3+ cells. Several IL-17+ and CD3+ 
cells can be seen in crypts and lamina propria of colon. Overlay shows IL-17 
signal do not colocalize with CD3 signal. Nuclei were counterstained with DAPI 
(blue). Images were taken at 200 times magnification. Scale bar represents 50 
µm. 
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To this point, we observed that IL-17 protein is of non T cell origin. To further 
clarify the cellular source of IL-17, double fluorescence was performed for anti-IL-
17 together with the marker anti-CD117 (c-kit) which is expressed by innate 
lymphoid cell type 3 (ILC3s). Interestingly, IL-17+ cells were found to be positive 
for CD117 as shown in Figure 5.18 (A) implicating the possible involvement of IL-
17 producing ILC3s which are known to be protective cells in the course of 
inflammation. Consequently, it was also seen that there exist IL-17 positive but 
CD117 negative cells as shown by a yellow arrow in Figure 5.18 (B) suggesting 
that there exists perhaps, heterogeneity of IL-17 producing cells, of innate origin. 
 
Figure 5.18: : IL-17+CD117+ double staining of colon tissue of ASCT patient. 
Green arrow indicates IL-17+ cells. Red arrow indicates CD117+ cells. Several IL-
17+ and CD117+ cells can be seen in crypts and lamina propria of colon. Overlay 
image shows that IL-17 signal colocalizes with CD117 signal in A&B as indicated 
by white arrow while yellow arrow indicates CD117 negative IL-17+ cell in image 
B. Nuclei were counterstained with DAPI (blue). Images were taken at 400 times 
magnification. Scale bar represents 20 µm.  
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5.2 Analysis of gene profiles during acute GI-GvHD (in 
collaboration with Medical University of Göttingen) 
As a part of Celleuorpe collaborative scheme, a digital PCR called ‘Fluidigm 
array’ was performed in Medical University of Göttingen (UMG-GOE). 192 
transplanted patients were chosen for the study. 200 ng of RNA was transcribed 
to cDNA as required by the Fluidigm array protocol and these samples used to 
profile the relevant genes during GvHD.  
5.2.1 Gene expression by fluidigm array correlates with gene 
expression by qPCR 
In the context of gastro-intestinal GvHD, there has always been scarcity of patient 
biopsies in transplant centres therefore the analyzes of gene profile is often not 
possible. Regensburg medical centre put an effort to collect patient’s biopsies 
after transplantation and the availability of biopsies motivated us to implement 
mRNA analysis in a bigger scale. In collaboration with the Medical University of 
Göttingen, gene array was performed using Fluidigm microarray digital PCR. 
Based on previous findings, 28 relevant genes (as listed in materials section 
3.9.2) were analyzed using digital PCR, among those seven genes that were 
already analyzed in University Medical Centre Regensburg were repeated to 
confirm the accuracy of digital PCR of Göttingen by conventional RT-qPCR of 
Regensburg.. Although it has been previously reported that both mRNA141 and 
micro RNA142 expressions are highly reproducible in digital PCR when compared 
to conventionally followed RT-qPCR, we aimed to confirm these results in 
transplanted biopsies. To further check the accuracy of digital PCR, different 
primer sequences were designed for three genes whereas the same primer 
sequences were used for rest of the four genes. It was observed that the 
expression of seven genes highly correlated between digital PCR and 
conventional RT-qPCR independent of the differences in primer sequences used 
as shown in Table 5.4. This correlation data suggests the accuracy and precision 
of digital PCR is highly comparable to conventional RT-qPCR.  
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Table 5.4: Correlation of gene expression by digital PCR and conventional 
qPCR. 
Nonparametric Spearman’s correlation was used to determine the correlation 
coefficient and significance between Fluidigm digital PCR and conventional qPCR 
mRNA expression.  
Genes 
No. of 
samples 
Correlation 
coefficient 
P value 
Primer 
sequence 
BATF 92 0.424 <0.001 Different 
DEFα5 176 0.753 <0.001 Same 
DEFβ4 176 0.143 0.05 Same 
FOXP3 175 0.317 <0.001 Same 
GPR109A 178 0.327 <0.001 Different 
IDO 151 0.473 <0.001 Different 
RORC 156 0.199 0.01 Same 
 
 
Of note, GAPDH was used as reference gene for digital PCR since 18S rRNA 
failed to show dissociation curve.  
5.2.2 Differential gene expression during acute-GI-GvHD 
As it became evident that the digital PCR correlates with conventional RT-qPCR, 
we aimed to analyze the gene expression in terms of GVHD and transplant 
related mortality. Due to the fact that samples are pre-amplified and GAPDH is 
used as reference gene, we choose only those samples that showed GAPDH 
expression within 15 cycles in the digital PCR. This restriction was chosen in 
order to make the analysis more precise. 
Gene expression was analyzed into terms of GvHD vs no GvHD patients for the 
selected genes. Table 5.5 shows the list of genes with their p values for the gene 
of interest. Of 21 carefully selected genes, only three genes were found to be 
significantly altered in GvHD as indicated by bold p values in the table. These 
genes were further analyzed with respect to different grades of GvHD and 
transplant related mortality. 
 
Table 5.5: Differential gene experssion during acute GI-GvHD. 
Gene expression was analyzed for non GvHD (n=57) vs GvHD (n=61) patients. 
Mann-Whitney test was performed to determine the significance.  
S.N Genes analyzed Alteration in GvHD p value 
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1 AHR Up 0.6 
2 CATH Up 0.5 
3 CYP24A1 Up 0.1 
4 CYP27A1 Down 0.007 
5 CYP27B1 Up 0.1 
6 CYP2R1 Down 0.4 
7 EBI3 Up 0.08 
8 GATA3 Up 0.2 
9 GC Down 0.8 
10 IL10 Up 0.2 
11 IL12A Up 0.6 
12 IL12B Down 0.7 
13 IL17 Up 0.4 
14 IL22 Up 0.2 
15 IL23 No change 0.9 
16 IL33 Up 0.07 
17 PXR Down 0.05 
18 REG3A Up 0.1 
19 TBET Up 0.1 
20 TNF Down 0.4 
21 VDR Down 0.007 
 
 
It was observed that CYP27A1, an enzyme involved in vitamin D synthesis, and 
VDR (vitamin D receptor) itself that recognizes the active vitamin D, is 
significantly downregulated during GvHD and the loss of the gene is associated 
with transplant related mortality as shown in Figure 5.19. Cyp27a1 is involved in 
first step of active vitamin D synthesis143. VDR binds to active form of vitamin D 
and is a well-defined immunomodulator that acts via NF-AT or NF-kB signaling 
pathways144. Significant loss of VDR at tissue level together with the loss of 
CYP27A1 could partially attribute to the exacerbation of inflammation during 
GvHD.  
Next, the correlation between CYP27A1 and VDR was calculated. To our surprise 
we observed a strong correlation between CYP27A1 and VDR expression with p 
value <0.001 and a correlation coefficient of 0.654 in 118 patients samples as 
shown in Figure 5.20 (A). When this correlation was further analyzed in terms of 
transplant related mortality (TRM), once again, loss of both CYP27A1 and VDR 
was found to be strongly correlated with TRM with a p value <0.001 and a 
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correlation coefficient of 0.647 in 112 patients as shown in Figure 5.20 (B). Taken 
together these data strongly reveal a sequential loss of vitamin D metabolism and 
processing that could lead to altered immunoregualtion which subsequently leads 
to severe inflammation in GvHD. This result could also partially explain the 
previously reported fact that transplanted patients depict low level of vitamin D in 
the serum145 that could possibly be accounted for the loss of CYP27A1 and VDR.  
 
 
Figure 5.19: Alteration of CYP27A1 and VDR gene expression during acute 
GI-GvHD. 
A. CYP27A1 significantly downregulates during aGI-GvHD when compared to 
non GvHD patients. C.There is significant loss of VDR mRNA during GI-GvHD 
when compared to non GvHD patients. N=118 (No GvHD=57 patients, Grade 1 
GvHD=38 patients, Grade 2-4 GvHD=23 patients). B. Loss of CYP27A1 is 
significantly associated with transplant related mortality. D. Loss of VDR is 
significantly associated with transplant related mortality. N= 115 (RRM=64 
patients, TRM=51 patients). ). Data were non-normally distributed therefore non-
parametric Kruskal-Wallis and Mann-Whitney test was performed to calculate p 
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values. Bar represents ± s.e.m. RRM=Relapse Related Mortality; 
TRM=Transplant Related Mortality; VDR=Vitamin D Receptor.  
 
 
Figure 5.20: CYP27A1 mRNA correlates with VDR mRNA and TRM occurs 
more frequently in patients with low CYP27A1/VDR expression. 
A. Scatter plot diagram of CYP27A1 mRNA and VDR mRNA with the correlation 
coefficient of 0.654 and p value <0.001. N=118 patients. B. Green circles 
represent patients with Relapse Related Mortality (RRM) or survival. Red circles 
represent patients with Transplant related mortality(TRM). Patients with reduced 
CYP27A1/VDR expression exhibited frequent TRM with the correlation coefficient 
of 0.647 and p value <0.001 when data were controlled for TRM. N=112 patients. 
Data were non-normally distributed therefore non-parametric Mann-Whitney test 
was performed to calculate p values. Data represents ± s.e.m. 
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Figure 5.21: Survival curve in relation to median CYP27A1 and VDR mRNA 
expression. 
A: Cumulative TRM in patients with low expression of CYP27A1 significantly 
increases (p log rank= 0.002) when compared with patients with high CYP27A1 
expression. B: Cumulative TRM in patients with low expression of VDR 
significantly increases (p log rank= 0.008) when compared with patients with high 
VDR expression. N= 63 patients.  
Next, patients were further classified into either low or high CYP27A1 and VDR 
based on their mRNA expression. Absolute median values of CYP27A1 and VDR 
expression were calculated and the patients were divided into ‘below median’ and 
‘above median’ group. Kaplan-Meier estimates for TRM are shown in Figure 5.21. 
Patients with less CYP27A1 mRNA showed significantly higher frequency of TRM 
than the patients with more CYP27A1 mRNA expression. Furthermore, a 
significant reduction of TRM was observed with a higher expression of VDR 
mRNA (p=0.001). These results collectively suggest that the vitamin D receptor 
along with the vitamin D related enzyme Cyp27a1 are lost during GvHD and that 
this possibly leads to a compromised immunosuppression.  
 
Cyp27b1 is another vitamin D related enzyme that are involved in synthesis of 
active form of Vitamin D146. Although there was no difference in CYP27B1 mRNA 
expression when compared in GvHD vs. no GvHD patients, this gene was found 
to be significantly altered when patients were divided into no GvHD, grade 1 
GvHD and grade 2-4 GvHD groups. While VDR and CYP27A1 were 
downregulated in GvHD, we found that CYP27B1 significantly upregulates during 
acute GI-GVD and the mortality due to transplant occurs frequently in patients 
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with high expression of CYP27B1 mRNA as shown in Figure 5.22. While the 
function of CYP27B1 in GI tract is least studied, it has been previously 
documented that in skin, when microbial pathogens bypass the damaged 
epidermal barrier and are recognized by TLRs, CYP27B1 is upregulated147. 
Furthermore, reports shows that CYP27B1 increase in response to injury and 
TLR activation148 suggesting the involvement of CYP27B1 in inflammatory 
reactions. These findings may explain that CYP27B1 expression in the GI tract is 
an indicator of inflammation which increases in GI-GvHD. 
Figure 5.22: Alteration of CYP27B1 gene expression during acute GI-GvHD. 
A. CYP27B1 significantly upregulates during severe aGI-GvHD when compared 
to non GvHD or mild GvHD patients. N=118 (No GvHD=57 patients, Grade 1 
GvHD=38 patients, Grade 2-4 GvHD=23 patients). B. Gain of CYP27B1 is 
significantly associated with transplant related mortality. N= 115 (RRM=64 
patients, TRM=51 patients). Data were non-normally distributed therefore non-
parametric Kruskal-Wallis and Mann-Whitney test was performed to calculate p 
values. Bar represents ± s.e.m. RRM=Relapse Related Mortality; 
TRM=Transplant Related Mortality. 
 
In addition of Vitamin D related genes, there was one more gene that was 
significantly altered in aGI-GvHD: Pregnane Xenobiotic Receptor (PXR). PXR is a 
nuclear hormone receptor that senses xenobiotic compounds and metabolize 
these compounds to avoid immune mediated inflammation149. PXR is well-known 
receptor for Rifaximin. It has been shown that rifaximin activates PXR that leads 
to maintenance of intestinal immune homeostasis149. Inhibition of NF-kB pathway 
is well accepted mechanism of PXR mediated immune suppression150.  
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In a cohort of 118 patients, PXR mRNA expression in the GI-tract of ASCT 
patients revealed a significant downregulation especially in patients who are 
severely affected by GvHD as shown in Figure 5.23 (A). This result partly 
explains the clinical fact that severe GvHD patients do not respond to rifaximin 
medication which could be due to the loss of responsive receptor. Furthermore, 
patients who died due to transplantation exhibited relatively low PXR expression 
which is nearly significant when compared to relapse related mortality (RRM) or 
surviving patients as shown in Figure 5.23 (B) 
 Figure 5.23: Alteration of PXR gene expression during acute GI-GvHD. 
A. PXR significantly downregulates during severe aGI-GvHD when compared to 
non GvHD patients. N=118 (No GvHD=57 patients, Grade 1 GvHD=38 patients, 
Grade 2-4 GvHD=23 patients). B. Loss of PXR is associated with transplant 
related mortality and is nearly significant. N= 115 (RRM=64 patients, TRM=51 
patients). Data were non-normally distributed therefore non-parametric Kruskal-
Wallis or Mann-Whitney test was performed to calculate p values. Bar represents 
± s.e.m. RRM=Relapse Related Mortality; TRM=Transplant Related Mortality 
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Next, we investigated the expression of PXR (rifaximin receptor) in relation to the 
type of gut decontamination regime used for transplanted patients. Patients were 
given either rifaximin (44 patients) or the combination of ciprofloxacin and 
metronidazole (74 patients). Although not significant, we observed an 
upregulation of PXR mRNA expression in patients treated with rifaximin when 
compared to patients treated with Cipro/metro as shown in Figure 5.24. This 
suggests a partial role of rifamixin in upregulating PXR at mRNA level. The 
reason why this upregulation is not significant can be attributed to several other 
factors such as loss of i) Paneth cells151, ii) loss of protective IL-17, iii) alteration 
of vitamin D related gene, iv) overall loss of PXR itself.  
 
Figure 5.24: Alteration of PXR gene expression after transplantation in 
response to types of gut decontimation. 
PXR mRNA depicts trend of upregulation when patients have rifaximin (44 
patients) for gut decontamination compared to patients with 
ciprofloxacin/metronidazole (74 patients). N=118. Data were non-normally 
distributed therefore non- mean parametric Mann-Whitney test was performed to 
calculate p value. Bar represents ± s.e.m. 
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5.3 Immunomodulatory effects of bacterial metabolite Indoxyl 
3-sulfate (I3S): implications for GvHD 
Maintained bacterial diversity is crucial for balanced immune system and normal 
immune function. Bacterias act on immune and non-immune cells by producing 
bacterial metabolites. The interplay between microbiome and immune system 
have gained significant attention in recent years partially due to the fact that the 
immune related diseases were the consequences of loss of microbial diversity in 
gut112,113,152. As such, alteration of gut microbiome is associated with autoimmune 
diseases, obesity153 , cardiovascular disease154 , and inflammatory bowel 
disease152.  
Indole derivatives such as indole-3-carbinol (I3C) and indirubin-3’-oxime (IO) 
exhibit immunosuppressive and anti-inflammatory effect on bone marrow derived 
DCs in mice155. A recent study reported that the decrease in urinary Indoxyl 3-
sulfate (I3S), an indole derivative, was associated with disrupted microbiome and 
poor outcome early after allogenic stem cell transplantation (ASCT) and that 
abundance of clostridia species such as Lachnospiraceae and 
Ruminococcaceae) were associated with high urinary I3S113. To analyze 
immunomodulatory effect of I3S, dendritic cells were cultured and treated with I3S 
as described in method section 4.5.3. Cell viability, DC surface marker and 
cytokine production, mRNA expression was analyzed. DCs were cocultured with 
allogenic T cells and thus cytokine production by T cells was followed.  
 
5.3.1 I3S does not induce apoptosis in monocyte derived DCs  
Since the effect of I3S has not yet been evaluated on human dendritic cells and 
the body of literatures have shown the cytotoxic effect of I3S, the extent of 
apoptosis and necrosis was initially examined in monocyte derived mature 
dendritic cells (mDCs). Immature DCs on day 5 were stimulated with LPS and 
simultaneously treated with varying concentration of I3S (1, 10,100, 500 and 1000 
µM). There was no observable difference in apoptotic cells in any concentration of 
I3S when compared to untreated control mature DCs (Figure 5.25). Similar effect 
was observed when I3S was added to the cells on day 0 (data not shown). 1-10 
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µM of I3S is present in healthy individuals with normal kidney function. Since 100 
µM and above I3S concentration represents physiologically toxic concentration for 
various other cell types including epithelial and endothelial cells, this study limited 
the I3S concentration up to 100µM.  
 
 
 
Figure 5.25: Apoptosis measurement of LPS stimulated mature DCs by 
Annexin V/7AAD staining. 
Immature DCs were stimulated with 100 ng/ml LPS +/- I3S for 48 hours. Viability 
was determined by Annexin V/7-AAD staining Control DCs were not treated with 
I3S. Live cells (represented in lower left quadrant) remained unchanged in I3S 
treated DCs when compared to I3S untreated control DCs. 
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5.3.2 I3S does not alter survival of mature DCs 
I3S did not seem to affect both survival and viability of mature DCs. Although at 
10µM DC growth seems to slightly increase (Figure 5.26 A), it is however not 
significant and, in addition, the viability tends to remain unaltered independent of 
I3S concentration (Figure 5.26 B). Therefore the concentration of 1µM, 10µM and 
100 µM were chosen for the subsequent experiments. 
 
Figure 5.26: Effect of I3S on survival of human monocyte-derived mature 
DCs. 
Immature DCs were stimulated with 100 ng/ml LPS +/- I3S for 48 hours. A. Cell 
counting was performed by means of a cell analyzer (CASY). B. Percentage of 
viable cells were determined by CASY. Bar represents mean + s.e.m of n=10 
individual donors. 
 
5.3.3 I3S alters LPS-induced changes in surface marker expression 
of mature DCs 
DCs are crucial in stimulating T cell and mounting appropriate immune responses 
to pathogens and inflammation. The effects of I3S on expression of several 
surface markers that are responsible for T cell stimulation was examined (Figure 
5.27). Due to the donor dependent variation in expression of protein, control DC 
was calculated as 100% expression of protein and I3S treated DCs were 
analyzed with respect to control. When I3S was added on day 5, and DCs were 
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exposed to I3S for 48 hours only, CD80 and CD86 were strongly downregulated 
while CD1a, CD83 and HLA-DR remained unaffected (Figure 5.27).  
 
Figure 5.27: Impact of I3S on surface marker expression of human 
monocyte-derived DCs. 
Graphical representation of CD1a, CD83, CD80, CD86 and HLA-DR expression 
on mDCs with or without I3S. Bars show the mean + s.e.m of n=8 individual 
donors for CD1a, CD83 and CD86 and n=7 individual donors for CD80 and HLA-
DR. *p<0.05, **p<0.01, * show significant differences between control and 
treatment (Kruskal Wallis and post-hoc by Dunn’s Multiple Comparison Test). 
5.3.4 I3S alters LPS-induced pro-inflammatory and anti-
inflammatory cytokines in monocyte derived mature DCs 
The effects of I3S on pro-inflammatory and anti-inflammatory cytokine production 
following LPS activation in monocyte derived mDCs were assessed. 100 ng/ml 
LPS induced production of pro-inflammatory cytokines such as IL-12 and IL-6. 
Monocyte derived mDCs exposed to varying concentration of I3S and 
simultaneously stimulated with LPS produced lower levels of pro-inflammatory 
cytokines (Figure 5.28). IL-12 and IL-6 were significantly downregulated in 
presence of I3S, whereas an anti-inflammatory cytokine IL-10 was significantly 
upregulated (Figure 5.28). I3S treatment to DCs on day 0 gave similar results 
(data not shown). Taken together, these results suggest that bacterial metabolite 
I3S is able to suppress the inflammatory response of LPS-stimulated DCs by 
inhibiting the pro-inflammatory mediators thereby promoting an anti-inflammatory 
mediator. 
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Figure 5.28: Downregulation of LPS-induced pro-inflammatory cytokines 
and upregulation of anti-inflammatory cytokine by I3S treated mature DCs. 
Cytokine release in the cell supernatant of mDCs was accessed by ELISA for IL-
12 (A), IL-6 (B) and IL-10 (C). Results are representative of eight individual 
healthy donors with n=8. Bars show the mean + s.e.m of n=10 individual donors 
for A & B, and n=7 individual donors for C. . *p<0.05, ***p<0.001, * show 
significant differences between control and treatment (Kruskal Wallis and post-
hoc by Dunn’s Multiple Comparison Test).  
 
 
5.3.5 I3S alters IL-12 pathway to mediate anti-inflammatory and 
immunoregulatory effect by mDCs 
 To analyze if the IL-12 alteration takes place at the transcriptional level or not, 
iDCs on day 5 were stimulated with LPS and treated with I3S for 4 hours. DCs 
were collected and RNA was extracted from the cells. Two step RT-qPCR was 
performed for IL-12A, IL-12B and AHR mRNA. Immature DCs which were not 
treated with either LPS or I3S did not express IL-12 gene. DCs stimulated with 
LPS expressed both IL-12A and IL-12B. In presence of I3S IL-12A and IL-12B 
showed strong trend of downregulation (Figure 5.29 A&B) which is in parallel with 
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reduction of IL-12 cytokine production. To our surprise, the receptor that binds to 
I3S, aryl hydrocarbon receptor (AhR), remained utterly unaltered (Figure 5.29 C) 
suggesting that the immunomodulation of DCs by I3S might not be attributed to 
AhR. In addition, ikB protein was analyzed by western blot. DCs were stimulated 
on day 5 with LPS and treated with I3S for five minutes. Phospho-protein was 
collected and ran through SDS-PAGE. Western blot showed that LPS 
unstimulated iDCs are able to express ikB and that the short term LPS stimulation 
downregulates ikBß expression as shown in Figure 5.30. When DCs were treated 
with I3S, ikB was partially restored with 10 µM I3S when compared to LPS 
stimulated iDCs (Figure 5.30). Taken together, these results suggest that the 
indole derivate Indoxyl 3-sulfate uses IL-12 pathway and NF-kB pathway to 
suppress inflammation.  
 
 
Figure 5.29: I3S mediates immunosuppression by altering IL-12 pathway but 
not AhR pathway. 
Monocyte derived immature DCs on day 5 were stimulated with 100 ng/ml LPS 
and varying concentration of I3S for 4 hours. Cells were collected lysed and IL-12 
trancription was evaluated by RT-qPCR for IL-12A (A), IL-12B (B) and AhR (C). 
mRNA expression was normalized to 18S rRNA expression. Bar represents mean 
+s.e.m of n=3 individual donors.  
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Figure 5.30: Effect of I3S on iKB expression. 
Immature DCs were stimulated with LPS, treated with I3S for 5 minutes. Protein 
lysates were collected and western blot was performed to access expression of 
ikBß. Representative blot is shown on left and densitometric anaylsis is shown on 
right. Bars show the mean + s.e.m of n=3 individual donors. 
 
5.3.6 I3S treated monocyte derived mDCs suppress the 
proliferation and cytokine production of antigen-specific T 
cells. 
To investigate if the alteration of surface marker and cytokine production by DCs 
also alters T cell proliferation, DCs and T cells from different donors (to ensure 
allogenic reaction) were co-cultured in the ratio 1:10 in mixed lymphocyte 
reactions, T cell proliferation was monitored on day 6. DCs were previously 
treated with I3S on day 5. Lymphocytes did not proliferate in absence of DCs 
(Figure 5.31 A). When lymphocytes were grown with I3S treated DCs, 
lymphocytes proliferated less as compared to the lymphocytes that are grown 
with control DCs (only LPS stimulation, no I3S treatment) Figure 5.31 A). 
Cytokines produced by DC stimulated lymphocytes were assessed by ELISA. As 
shown in Figure 5.31 B, C&D, lymphocytes produced significantly lower amount 
of IFN-y and TNF while IL-10 showed trend of downregulation when stimulated 
with I3S treated DCs as compared to I3S untreated control DCs. Unstimulated 
lymphocytes were not able to produce cytokines (Figure 5.31 B, C& D). Similar 
results were obtained when lymphocytes were stimulated with DCs that were 
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previously treated with I3S on day 0 (data not shown). Taken together, these 
results suggest that I3S not only modulates dendritic cell function but also 
indirectly modulates the T cell function at cytokine level.  
 
 
Figure 5.31: Co-culture of I3S treated mDCs with allogeneic T cells. 
DCs treated with/without I3S were cocultlured with allogenic T cells at 1:10 ratio. 
A. Proliferated T cells were counted on day 6 by means of CASY for n= 8 MLR 
settings. B, C&D. T cell mediated cytokines were accessed on day 5 by means of 
ELISA for IFN (n=8), TNF (n=8), and IL-10 (n=3) respectively. Bars show the 
mean + s.e.m. *p<0.05, **p<0.01, ***p<0.001, * show significant differences 
between control and treatment (Kruskal Wallis and post-hoc by Dunn’s Multiple 
Comparison Test). 
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6 Discussion and conclusion  
6.1 Immune cell infiltrates during acute GI-GvHD 
The mucosa of gastro intestinal tract is unique among tissues in that it is in 
continuous contact with super dynamic microbial community and is populated by 
heterogeneous composition of immune cells which have crucial function in 
protection and immune homeostasis156. The major form of adaptive immunity in 
the gut is humoral immunity via B cells and cell mediated immunity via T cells2. T 
cells are found within the gut epithelial layer, spread throughout the lamina 
propria and submucosa, and within peyer’s patches. In GI tract, different subsets 
of effector CD4+ T cells are induced by and protect against different microbial 
species. The helper CD4+ T cells secret different cytokines that are specialized 
for particular types of antimicrobial responses2. In humans most the the 
intraepitheilal T cells are CD8+ T cells which are responsible for direct cytolysis of 
foreign organisms or cells with altered antigen expression. The reason for CD8+ T 
cell abundance can be attributed to the fact that GI tract is continuously exposed 
to antigens and that more CD8+ T cells are required to keep control of invasion of 
harmful organisms. It is well accepted that mature donor T lymphocytes present 
in stem cell inoculum during stem cell transplantation is the major cause of graft 
vs host disease but at the same time these T cells promote hematopoietic 
engraftment, reconstitute T cell immunity and mediate potent beneficial anti-tumor 
effect i.e. graft vs leukemia effect157.  
6.1.1 Infiltration of CD4+ T cells and CD8+ T cells during acute GI 
GvHD 
Both CD4+ and CD8+ T cells have critical roles in the pathogenesis of GvHD. Of 
note, GvHD is the result of naïve T cell response and that memory T cells do not 
include GvHD158,159. The pathogenicity of helper T cells has been attributed to 
CD4+ T cell subsets like Th1, Th2 and Th17 that act via proinflammatory 
cytokines production. The pathogenicity of CD8+ T cells has widely been 
attributed to perforin and granzyme pathway160.  
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Infiltration of CD4+ T cells was analyzed in 199 patients after stem cell 
transplantation by applying single antibody immunohistochemistry. No significant 
difference existed between GvHD and non GvHD patients in terms of CD4+ T 
cells infiltration but we found that the CD4+ T cells expression was highly 
correlated with apoptosis of epithelial cells and infiltration of CD8+ T cells. In one 
study, Landfired et al. reported in cohort of 64 transplanted patients that the 
infiltration of CD4+ T cells (as well as neutrophils) significantly reduced in 
NOD2/CARD15 SNP patients when compared to wildtype recipient161. In another 
study, Holler and co-workers elegantly demonstrated that NOD2/CARD15 
polymorphism associated with GvHD and overall survival after ASCT162,163. 
Therefore it can be well noted that NOD2 polymorphism and reduction of CD4+ T 
cells infiltrates is associated with GvHD. We however did not see significant 
change in overall CD4+ T cell infiltrates according to GvHD grades but the 
correlation of CD4+ T cell infiltrates with CD8+ T cells and epithelial apoptosis 
clearly suggest indirect participation of CD4+ T cells in exacerbation of GvHD 
preferentially via FasL/TNF dependent mechanisms or by helping CD8+ T cells. 
Furthermore, it can also be hypothesised that the majority of CD4+ T cells could 
be effector or memory T cells that is known to participate in GVL effect but not 
GvHD which could possibly explain why there is no difference in CD4+ T cells 
infiltrates during GvHD but strong correlation exists with CD8+ T cells and 
apoptosis of epithelial cells in the gut.  
 
When CD8+ T cells were analyzed in 197 transplanted patient’s gut biopsies, 
there was a significant increase of these cytotoxic T cells along with exacerbation 
of GvHD. In addition, CD8+ T cells infiltrates were significantly correlated with 
infiltration of CD4+ T cells, loss of crypts in gut and the apoptosis of epithelial cells 
in gut. This suggests i) strong interaction of CD4+ T cells and CD8+ T cells in gut; 
ii) strong cytolytic activity of CD8+ T cells in destruction of crypts (Paneth cells) 
and epithelial cells of gut. Therefore, increase in CD8+ T cells could indicate 
strong inflammation rendering crypt and epithelial destruction. As a matter of fact 
infiltration of CD8+ T cell is a well established hallmark of GvHD, therefore our 
result confirms CD8+ T cell mediated cytotoxicity in the gut of large number of 
patients after stem cell transplantation.  
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6.1.2 Infiltration of Foxp3+ and IDO+ cells during acute GI GvHD 
As clear as it is that GvHD is caused by uncontrolled T cell mediated 
inflammation, it is unambiguously known that Foxp3+ regulatory T cells are 
responsible for subsiding uncontrolled T cell response thus mantianing self-
tolerance42. For the first time in the science of stem cell transplantation, we 
showed the status of Tregs infiltrates in 199 gut biopsies of transplanted patient 
by performing Foxp3 immunohistochemistry and found that Tregs significantly 
increases during GvHD. Body of literatures demonstrated loss of Tregs frequency 
subsequent to GvHD59,164-167. Our result is in contrast with existing literatures and 
hypothesis that extreme GvHD is partly due to loss of Tregs leading to 
compromised regulation in the inflammatory milieu. We observed increase of 
Foxp3 protein in the gut of ASCT patients. This result was further supported by 
the increase of FOXP3 at mRNA level as well and the strong correlation of Foxp3 
at protein and mRNA level. One main reason for these differences in our data and 
previous data is that most of the previous studies evaluated Tregs in peripheral 
blood. Our study is entirely focused on the intestinal tissue which is the major 
organ to be damaged in acute GI GvHD. We observed that infiltration of Tregs 
were significantly higher in patients who showed histological and clinical signs of 
GvHD. To our knowledge, there are only three reports till now on Foxp3 
expression on intestinal tissue59-61. Two of these studies60,61 reported that Foxp3 
increases during GvHD and are in harmony with our observation. It can be 
speculated that the increase in Foxp3+ cells in response to inflammation is a 
counter regulatory mechanism of T cells to subside inflammation during GvHD. It 
could also reflect a greater degree of systemic T cell activation in this population. 
Another possible explanation would be the exhaustion of Tregs. Given that the GI 
tract is a secondary lymphoid organ where immune cells can differentiate de novo 
based on environmental cues, we can speculate that these Tregs are rather 
induced de novo in response to pronounced inflammation. Unfortunately, natural 
and induced Tregs could not be individualized in this study due the lack of 
marker/s that differentiates natural and induced Tregs.  
 
Next, we were interested to find out the cellular source of Foxp3. For this, single 
immunofluorescence for Foxp3, CD4 and CD8 was individually established. 
Double immunofluorescence was performed for CD4 and Foxp3 together. It was 
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observed that the huge proportion (90%) of Foxp3+ cells were CD4 positive. 
When these double positive cells were analyzed on 22 patients, CD4+Foxp3+ 
double positive cells were upregulated in GvHD and were almost significant 
supporting immunohistochemistry result of Foxp3 expression. To our surprise, 
CD4 negative Foxp3+ cells were detected insinuating the existence of new 
population of Foxp3+ cells that are not of CD4 origin. When double 
immunofluorescence was performed for CD8 and Foxp3 together, we found CD8 
positive Foxp3+ cells that showed increasing trend with the exacerbation of 
GvHD. CD8+Foxp3+ Tregs has been previously described in literatures and found 
to be capable of supressing T cell responses in experimental model of 
autoimmunity of allergen exposure56,168. In terms of GvHD, Beres and co-workers 
demonstrated that the suppressive population of CD8+ Foxp3+ Tregs are induced 
early during GvHD in mice model. Analysis of these Tregs population are highly 
missing in clinical spectrum of GvHD however Zheng and colleagues recently 
reported that human CD8+Foxp3+ T cells that were induced in vitro were able to 
supress GvHD in a humanized mouse model169. Therefore it can be noted that 
human CD8+ Foxp3+ Tregs might have suppressive ability in clinic. In our study, 
although CD8+ Foxp3+ Tregs were only up to 10% compared to total Foxp3+ 
Tregs, this small population might have serious contribution in amelioration of 
GvHD. Furthermore, induction of CD8+ Foxp3+ Tregs was observed only after 
grade 2 GvHD with huge variation in cells per HPF due to steroid treatment. 
Patients who received more than 20 mg/kg of steroids depicted less CD8+ Foxp3+ 
Tregs than the paitents who received 0-20 mg/kg steroids per day (data not 
shown). This suggests that protective CD8+ Foxp3+ Tregs are compromised in 
patients who receive high dose steroids and are susceptible to GvHD related 
death. Similarly, lesser CD4+ Foxp3+ Tregs were observed in grade 2-4 patients 
receiving high dose steroids (data not shown). These findings provide preliminary 
evidence that silencing the immune system by steroids has adversary effect on 
protective Tregs population in GvHD patients.  
 
 
Next, indoleamine-2,3 deoxygenase (IDO) was analyzed by single antibody 
immunohistochemistry in gut of 193 patients after stem cell transplantation. We 
observed significant upregulation of IDO with increasing GvHD. Increase in IDO 
at protein level is supported by significant increase of IDO mRNA (n=190) at 
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transcriptional level and a significant correlation of between IDO protein and 
mRNA expression. Increased IDO production during GvHD related inflammation 
may reflect a reactive release of immunosuppressive mediators which is perhaps 
initiated to balance immune reactions. Significant correlation between IDO 
expression and Foxp3 expression both at protein and mRNA level indicates that 
immunosuppressive IDO might have favoured Foxp3 expression as IDO is well-
known to induce peripheral tolerance by increasing Tregs80,81. IDO catabolizes 
essential amino acid tryptophan into kynurenine, an agonist for Aryl Hydrocarbon 
Receptor (AHR). AHR is necessary for generating Tregs67. As AHR is an agonist 
for several bacterial metabolites including indole and their derivatives, it may turn 
out well to state that the balanced bacterial diversity is required for toleregenic 
Tregs generation.  
 
Of note, infiltration of neutrophils highly correlated with Foxp3 and IDO 
expression in this study. Neutrophils are known to interefere with T-cell 
proliferation as neutrophilic myeloid-derived suppressor cells (MDSCs)170. 
Recently, Pillay and colleagues reported that the subset of mature human 
neutrophils that can be systematically induced in response to acute inflammation 
are able to suppress T cell function171. Experimental models have demonstrated 
that the prolonged antibiotic treatment leads to reduced neutrophil number172 and 
a severe neutropenia occurs in germ-free animals 173 suggesting a close link 
between microbiota and neutrophils. Recent evidence suggests that the bacterial 
metabolites such as SCFAs regulate neutrophil-mediated inflammation through 
GPR43 expression at high levels by neutrophils174. In this light, we can 
hypothesize that the neutrophilic MDCSs are highly regulated by intact 
microbome. MDSCs not only suppress T cell activity but also stimulate Tregs175. 
In one recent observation by Jitschin and colleagues, monocytic MDSCs were 
able to suppress T cells and induce Tregs presumably via increased IDO 
activity176. Taking into account that we observed strong correlation between 
neutrophils, Foxp3+ cells, and IDO+ cells, it can be hypothesized that MDSCs 
infiltrate to the site of acute inflammation during GvHD trying to subside T cell 
mediated inflammation by enhancing IDO and Tregs, and could be potential 
target in GvHD treatment.  
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6.1.3 Infiltration of IL-17+ cells during acute GI GvHD 
IL-17 received considerable attention in past few years when several literatures 
reported inflammatory response of IL-17 in GvHD mice model102,103. Contrary to 
the belief that IL-17 increases and possess severe inflammation during GvHD, we 
found significant downregulation of IL-17 protein when IHC was performed on gut 
samples of 197 transplanted patients. Furthermore, at mRNA level, the 
transcription factor of IL-17- RORC, also significantly downregulated along with 
increasing GvHD in 197 patients. We reported that GvHD is attributed to loss of 
IL-17. In addition, IL-17 protein and RORC mRNA significantly correlated with 
each other and that the transplant related mortalityoccured more frequently in the 
patients expressing low IL-17 and low RORC. Our observations do not obey the 
dogmatic belief that IL-17 contributes to GvHD. Our findings suggest that IL-17 
cells are diminished in GvHD and their loss contributes to higher GvHD and 
greater transplant related mortality. This is a first report to demonstrate loss of IL-
17 in patient’s gut biopsies in a large number of patients. However, a possible 
solution of the obvious discrepancy might be IL17 production by non-T cell 
populations. 
 
We therefore exploited double immunofluorescence on colon biopsies to find out 
cellular source of IL-17 cells. For this 39 samples were analyzed for IL-17+CD4+ 
double staining. Surprisingly, no double positive cells were observed. All the IL-
17+ cells identified in the colon were CD4 negative. This is the first clinical 
evidence to state that IL-17 production in colon is not mediated by Th17. It is 
known that gamma-delta T cells177 and invariant natural killer T cells178 are other 
major source of IL-17 production. To clarify if IL-17 belongs to other T cell types, 
we again exploited double immunofluorescence of IL-17+CD3+ and analyzed 39 
heterogeneous colon samples. Again to our surprise, IL-17 signal did not 
colocalize with CD3 signal providing first clinical evidence that IL-17 cell in colon 
are produced by non T cells are perhaps are of innate origin. Due to the 
complexity of double immunofluorescence technique on formalin fixed paraffin 
embedded (FFPE) biopsies we could not differentiate between low IL-17 
expression and background. Therefore we might have omitted cell with low IL-17 
expression (if any) that resembled background. Only the bright distinct IL-17 
signals were chosen that were reliable enough to be a true signal. Our study 
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accounts for distinct and clean IL-17 expression that was both CD4 negative and 
CD3 negative. It is however quite unlikely to have true technical error as we 
clearly observed CD4+IL-17+ in the colon of Crohn’s disease patients which was 
distinctly bright and clean. The overall IL-17 expression was analyzed by two 
different analysers and observed significant downregulation of IL-17 during 
GvHD. This confirms the specificity of IL-17 antibody and that immunofluorescent 
staining is in harmony with immunohistochemical staining.  
Recently, a whole new set of immune cells have been identified, termed as innate 
lymphoid cells (ILCs) which plays central role to preserve epithelial integrity and 
tissue immunity81. ILCs mirrors helper T cell function by producing similar 
cytokines and expressing similar transcription factors for their development but 
lacks lineage marker83. Perhaps innate immunity alone is not sufficient to combat 
very early infections and that T cell related cytokines are required to mount 
effective immune response which is supplemented by ILCs. This could be one of 
the reasons why ILCs exists.  
 
In past 10 years, there was a rise of influential works in understanding ILCs with 
the major focus on group 3 ILCs. Group 3 ILCs express RORC as a major 
transcription factor and produce IL-17 and IL-2283. Recent work by Hanash and 
colleagues demonstrated ILCs that produce IL-22 were associated with protection 
of the intestinal stem and progenitor cell compartment and mature epithelium 
from inflammatory tissue damage in an experimental model of GvHD41. However, 
during GVHD, there is loss of the IL-22-producing ILCs necessary for limiting that 
inflammatory tissue damage. We were however unable to establish IL-22 
staining. Nevertheless, IL-22 producing ILCs also produce IL-17179, and in our 
study these IL-17 are lost, we hypothesized that innate lymphoid cells are the 
major source of IL-17 and the decreased frequency of IL-17 producing ILCs 
renders higher GvHD. For this, IL-17 was colabelled with CD117 (c-kit), a well-
known marker for group 3 ILCs. Majority of IL-17 signal colocalized with CD117 
signal suggesting that IL-17+ cells are probably group 3 innate lymphoid cells that 
are involved in tissue repair and immune homeostasis. At the same time, we 
found very few IL-17+ cells that were negative for CD117 marker. This confers the 
heterogeneity of innate IL-17 population and confirms that there are several 
innate immune cells responsible of IL-17 production. Our findings have several 
limitations. Since mast cell also express CD117 and produce IL-17, we cannot 
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ascertain that all the CD117+ IL-17+ cells are ILCs. These could be a mix 
population of ILCs and mast cells. Furthermore, ILCs cannot be directly 
demonstrated by microscopy due to the lack of definite marker. If only one could 
combine IL-17 and CD117 together with CD127, group 3 ILCs can be confirmed. 
We were unable to establish CD127 staining and we were unable to establish 
triple staining due to the complexity of immunofluorescence on FFPE slides.  
It is necessary to explore the heterogeneity of innate IL-17 to understand its role 
in GvHD. Triple staining may help us to decode several different IL-17 producing 
cells broadening our understanding in the pathogenesis of GvHD.  
6.2 Differential gene regulation during acute GI GvHD 
Several reports have intensified the importance of determining the gene 
expression profiling which helps identify the candidate genes involved in disease 
diagnosis, prognosis and outcome of GvHD180-182. In this study, an advanced 
digital PCR ‘Fluidigm’ was used to monitor gene profiling. Firstly, the accuracy 
and the reproducibility of Fluidigm were determined by repeating few genes that 
were previously analyzed in University Hospital Regensburg. We found that 
digital PCR Fluidigm readily reproduce the conventional qPCR data which are 
indifferent to the primer sets. We and others141 reported that mRNA analysis by 
Fluidigm is as accurate as routinely followed qPCR and that Fluidigm technique 
should be incorporated in scientific research that substitute multiple PCRs at a 
time.  
 
To our knowledge, this is the first study to evaluate gene profile in gut biopsies of 
GvHD patients. Out of several profiled genes, CYP27A1, CYP27B1, VDR and 
PXR turned out to be differentially regulated in GI tract of GvHD patients. 
CYP27A1-an enzyme associated with vitamin D synthesis, and vitamin D 
receptor were significantly downregulated in GvHD. Patients with less of these 
mRNAs displayed significantly higher TRM. Based on these results we 
hypothesize that during GvHD vitamin D metabolism is altered due to reduced 
CYP27A1 which might lead to reduced systemic vitamin D level. Loss of VDR 
may reflect the fact that GvHD patients are vulnerable to vitamin D deficiency 
even when external supplementation is provided. A recent study study from 
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Meckel and colleagues revealed an interesting fact that serum 25(OH)D3 
concentration is inversely related to the disease severity in the cohort of 230 
ulcerative colitis patients183. They also showed that serum 25(OH)D had a dirct 
association with expresson of colonic mucosal VDR and tight junction proteins183. 
In another study, using VDR knock-out mice, authors illustrated that VDR is 
essential for epithelial tight junction protein associated gene-claudin 2 (CLDN2).  
Together with these recent findings one might hypothesize that the loss of 
CYP27A1 leads to reduced 25(OH)D level: in combination with the loss of VDR, 
epithelial junction might be compromised which might support the development of 
severe GvHD. Taken together, our results indicate the need to supplement 
patients undergoing stem cell transplantation with vitamin D since this might help 
to preserve epithelial structures and therefore ameliorate gut GvHD. Few studies 
have reported that vitamin D deficiency is related to development of chronic 
GvHD184,185. Kreutz et al. demonstrated the marked decline of vitamin D 
metabolites in the course of allogenic stem cell transplantation145 providing 
emphasis on role of vitamin D on pathophysiology of GvHD. Furthermore, 
Kaplan-Meier estimates showed that the incidence of transplant related mortality 
is higher in patients expressing low level of CYP27A1 and VDR. It is worth to 
speculate that these vitamin D related parameters may represent the potential 
biomarkers and therefore further studies are required to find out the mechanism 
of loss of CYP27A1 and VDR which might contribute to vitamin D related therapy 
in future. It is well realized that the polymorphism in VDR is associated with poor 
survival following GvHD186. Subsequently, cyp polymorphism is associated with 
increased TRM after SCT187. Therefore it is perhaps noteworthy to study the 
vitamin D related gene expression with respect to SNPs. In addition, the cellular 
source of these changes needs to be clarified.  
 
On the other hand, CYP27B1 upregulated in GvHD and was associated with 
increased mortality and reduced survival. CYP27B1 is responsible for the 
synthesis of biologically active form of vitamin D188. Few reports suggest that 
CYP27B1 upregulates in inflammatory phenomena147,148. Our finding is in line 
with the concept that CYP27B1 might indicate the inflammatory mediator of 
GvHD and could be used as a marker to predict GvHD mediated inflammation.  
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Pregnane-X-Receptor (PXR) turned out to be another possible candidate as a 
biomarker for GvHD progression. PXR is able to sense and metabolize xenobiotic 
compounds and suppresses inflammation149. This study showed significant 
downregulation of PXR mRNA in patients who suffered from GvHD. Deceased 
patients depicted relatively less PXR expression. It can be noted that PXR acts as 
an anti-inflammatory mediator which are lost during GvHD related inflammation. 
Recent study suggests that rifaximin (a rifamycin-derivative frequently used for 
treatment of traveler’s diarrhea) is a potential ligand for PXR189. In one report, 
Weber et al. demonstrated that rifaximin treated patients had preserved intestinal 
microbial balance in ASCT patients190. This suggests the involvement of PXR in 
balanced microbial diversity. Although insignificant, our findings that rifaximin 
treated patients showed higher PXR mRNA expression when compared to 
ciprofloxacin treated patients is in line with Mencarelli and co-workers who 
reported that rifaximin increases the expression of PXR in the in vitro model of 
human epithelial cell191. PXR mRNA expression however did not show any 
differences in Kaplan-Meier estimates therefore we were not able to predict 
patient’s survival with PXR mRNA expression.  
6.3 Role of bacterial metabolites in GI GvHD 
Human body harbors a dynamic community of nearly 100 trillion intestinal 
bacteria that are inevitable for the development, education and normal function of 
immune system192. Bacterial metabolites such as short chain fatty acids (SCFAs), 
indoles and their derivatives are essential to maintain immune balance in mice 
and men 36,113,155,193. Since body of literatures have provided evidence that 
microbes and microbial metabolites are important for the maintenance of immune 
tolerance, in this study we hypothesized that indoxyl 3-sulfate, a bacterial 
metabolite, have immunomodulatory effects on human dendritic cells.  
Here we reported that the bacterial metabolite I3S promotes anti-inflammatory 
and immunoregulatory DCs in vitro. So far, I3S is best known marker for chronic 
kidney diseases and cardiovascular diseases in patients during renal failure and 
this metabolite is toxic for epithelial and endothelial cells at the concentration of 
CKD patients 194. However, our results appear to support the findings that 
microbes-derived indole and derivatives thereof, such as indole-3-carbinol (I3C) 
   103 
and indiriubin-3’-oxime (IO) modulates the immune function by altering the 
function of DCs 155. Unlike epithelial and endothelial cells, DCs maturation and 
viability remained unaffected in the presence of I3S which perhaps suggests a 
symbiotic survival mechanism of indoxyl 3-sulfate producing bacteria (clostridia 
species) and immune cells. The maturation process and antigen presenting ability 
of DCs was also unaltered by I3S suggested by normal expression of HLA-DR. 
However, co-stimulatory molecules CD80 and CD86 were downregulated under 
the influence of I3S. CD1a and CD83 on the other hand were not affected. Taken 
together, these data suggests that the bacterial metabolite I3S does not alter first 
signal of T cell activation i.e. antigen presentation by HLA-DR molecule but 
strongly alters second signal i.e. downregulation of co-stimulatory molecules on 
DCs that are necessary for T cell activation.  
The third signal, cytokine production by DCs, was accessed by ELISA. Secretion 
of pro-inflammatory cytokines, IL-12 and IL-6 was strongly downregulated in 
presence of I3S whereas, IL-10, an anti-inflammatory cytokine strongly 
upregulated in presence of I3S. Our results further supports the findings by 
Benson and colleagues reported that the indole derivatives can alter cytokine 
production by DCs thus induce immunoregulatory nature 155. Downregulation of 
surface marker CD80 and CD86 and the suppression of IL-6 production is in line 
with the findings by Orabona and colleagues that IL-6 production requires CD80 
and CD86 expression 195. Furthermore, IL12A and IL12B mRNA decreased at 
transcriptional level implicating that I3S uses IL-12 pathway to suppress 
inflammation mediated by DCs. Expression of IκB protein (inhibitor of NF-kB) in 
presence of I3S suggests that NF-kB pathway is possibly inhibited by I3S thus 
DCs acquire anti-inflammatory properties. It is known that I3S is a ligand of aryl 
hydrocarbon receptor (AhR) 196 and that AhR regulates NF-kB pathway 197. We, 
however, did not observe alteration of AhR at transcriptional level but the slight 
alteration of suppressor of NF-kB reveals that I3S can modulate DC function 
partly by altering NF-kB perhaps via AhR independent pathway. This hypothesis 
is supported by the findings by Benson and co-workers where alteration in murine 
DC surface marker expression, cytokine production, and gene transcription were 
not entirely dependent on AhR 155.  
To further explore whether these immunomodulatory DCs alter function of 
lymphocytes, I3S treated mDCs were co-cultured with lymphocytes isolated from 
healthy subjects. In the set of allogenic mixed leukocyte reaction, flow cytometry 
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revealed no difference in proliferation and expression of CD4+ T cells and CD8+ T 
cells (data not shown). There were no alterations in the proliferation of 
CD4+CD25+FOXP3+ cells along with unaltered expression of AhR at 
transcriptional level. Bacterial metabolites (species of Clostridia) such as short 
chain fatty acid, namely butyrate, are potential Tregs inducers 51,198. Indole and its 
derivatives, which are also produced by the species of Clostridia are reported to 
generate Tregs in-vitro 199. Indoxyl 3-sulfate, however, did not seem to affect the 
differentiation of Tregs. This can be partially explained by unaltered AhR, as it is 
known that AhR is necessary to develop Tregs 200. Finally, we have found strong 
reduction in cytokine production in MLR settings. IFN-y and TNF were 
significantly downregulated when lymphocytes were differentiated with I3S 
treated mDCs. Reduction of IFN-y production could be the result of decreased IL-
12 production by mDCs followed by decreased T cell proliferation. To our 
surprise, IL-10 also depicted trend of downregulated in our MLR settings similar 
to the findings of Bansal and colleagues199. We assume that the regulatory 
criteria of lymphocytes is defined by the extent of inflammatory criteria, that is, in 
reduced inflammatory milieu, regulatory milieu also declines.  
Collectively, we have demonstrated that I3S is beneficial to induce anti-
inflammatory and immunoregulatory dendritic cells. The alteration in DC 
phenotype and function is possibly IL-12 pathway dependent. Altogether, we 
showed that I3S can modulate immune function by modulating cytokine levels. 
Our result supports the findings by Weber and colleagues that microbiota-derived 
indole and metabolites thereof are relevant counterpart of human immune system 
in protection against inflammation and for complex immune balance. It is however 
still hard to explain how the complex immune balance is achieved. In a much 
broader term we hypothesize that the bacterial metabolites like indoxyl 3-sulfate 
is a classic example of commensality. Tolerogenic immune system firstly prevents 
immune reaction against the bacteria itself which provides them a survival 
advantage. Secondly, the tolerogenic immune environment influences the 
inflammatory host immune system in general to avoid excess inflammation. 
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6.4 Conclusion and Perspective 
Since the early beginnings, in the 1950’s, hematopoietic stem cell transplantation 
(HSCT) has become an established curative treatment for an increasing number 
of patients with life-threatening hematological, oncological, hereditary and 
immunological diseases. This has become possible due to worldwide efforts of 
preclinical and clinical research focusing on issues of transplant immunology, 
reduction of transplant-associated morbidity and mortality and efficient malignant 
disease eradication. In the light of GvHD, gastrointestinal tract represents the 
major target organ of GvHD related inflammation. In spite of our broad 
understanding on the pathophysiology of GvHD, the actual GvHD biology of GI-
tract remains poorly understood which is dominantly due to the lack of biopsies 
from GI tract of patients. In this study, we exploited huge number of gut biopsies 
from transplanted patients and analyzed several relevant players in GvHD. 
 
Likewise, treatment has not improved in the last 20 years and the outcome of 
steroid resistant acute GvHD remains poor with only 30-40% survival which also 
reflects the insufficient understanding of pathophysiology201.  
The results of our study show that rather than effector cell population, 
immunoregulation seems to be most prognostic in GvHD. This seems to be true 
for the observed IDO – Foxp3 pathway, but also for the potential role of IL17+ 
cells. 
 
Increase of regulatory proteins such as Foxp3 and IDO with increase in GvHD 
severity represents previously unrecognized regulatory loop in GvHD. Existence 
of CD8+ Foxp3+ Tregs provides novel insight in existence of different population 
of Tregs that may well turn out to be previously unrecognized protective cells in 
GvHD, but further studies are needed which also address the question of 
involvement of natural versus induced Tregs. Association of Foxp3+ Treg infiltrate 
with IDO strongly suggests that the majority of cells observed in our study are 
inducible Tregs but confirmation by more complex staining is needed. 
Understanding of regulatory T cells has advanced significantly in both preclinical 
and clinical models for GvHD. Our data do not argue against the clinical 
application of natural Tregs where the next big challenge is to generate large and 
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pure enough Tregs with stable Foxp3-expression in a cost effective way. A further 
clinical problem is the optimal time point of Tregs application – if Tregs are 
applied to treat refractory GvHD there may be a substantial delay between 
indication and application and dampen the chance of successful interference due 
to irreversible damage. Furthermore, the impact of ongoing immunosuppressive 
drugs on Treg function has to be considered in clinical trials as it is also 
suggested by the effect of higher doses of steroid treatment on regulatory cell 
expression. 
Therefore a deeper understanding of function of the different subpopulations of 
Foxp3+ Tregs preferentially induced and natural Tregs is still needed and crucial 
to understand the role of these immunosupressors in allogeneic HSCT. 
Furthermore the role of CD8+ Tregs still remains unclear. As Tregs may undergo 
changes depending on the inflammatory environment they are facing, modulation 
of a Treg promoting environment seems important in addition to therapeutic and 
prophylactic application. 
 
The fact that IL-17+ cells are of innate origin demands a further extended vision in 
pathophysiology of GvHD and approaches shall be introduced to protect innate 
IL-17+ cells which may have crucial role in intestinal epithelial cell protection.  
 
A still unresolved question is the role of steroid treatment on some of the 
observed effects. It may well be that FoxP3 expression and regulatory T cells are 
affected by steroids and that the treatment of GvHD in this way contributes to 
further loss of immunoregulation. As we used only onset or screening biopsies for 
our analysis of TRM, however, a steroid effect on these data is unlikely. 
 
Bacterial diversity shapes immune system. Therefore effort shall be made to 
analyze immune cell in relation to the bacterial diversity which will clarify the 
importance of microbiota in influencing immune cells. Here we showed the 
bacterial metabolite indoxyl sulfate induce tolerogenic DCs in vitro. We observed 
that indoxyl sulfate is involved in downregulation of pro-inflammatory cytokines 
and upregulation of anti-inflammatory cytokine. It is well accepted that correct 
bacterial diversity is required for immune homeostasis. Bacterial metabolites like 
short chain fatty acids are involved in maintaining the integrity of epithelial cells, 
generate Tregs, induce tolerance and maintain immune balance. Therefore it is 
   107 
quite possible that immune cell infiltrates are highly controlled by diversity of 
bacteria. It seems very important to understand why and how tiny micro-organism 
can alter entire immune response in human beings. Understanding the effective 
role of protective bacteria and their metabolites in inflammatory diseases like 
GvHD and attempt to preserve the bacterial diversity may contribute well to 
establish immune homeostasis in ASCT patients. The immunomodulating effects 
of bacterial metabolites as shown for 3IS in this study strongly suggests that the 
microbial environment is a major player in this context, and it is well possible that 
restoration of a protective microbiome needs to precede Tregs application or 
other immunoregulatory interventions. 
 
Furthermore, biomarkers that allow early identification of patients at risk are 
urgently needed. This will help clinicians to choose right treatment early on time 
before the major changes have already damaged target organs. We showed that 
vitamin D related genes such as CYP27A1 and VDR could be a potential 
biomarker in future for which further research is needed. Biopsy derived markers 
have to be evaluated against newly established serum markers117 in prospective 
studies. A special effort should be made to detect early biomarkers as they might 
allow risk adapted early treatment and thus prevent irreversible damage. 
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7 Summary 
Acute Graft vs Host Disease (aGvHD) after allogenic stem cell transplantation is 
caused by activated donor T cells after recognition of recipient minor or major 
HLA antigens, which are presented after conditioning mediated inflammation or 
activation of danger signals. Donor T cells attack epithelial structures on target 
organs, especially in the GI tract. Damage of target organs is attributed to 
cytotoxic T cells along with helper T cells and their pro-inflammatory cytokines. 
Natural regulatory T cells are able to dampen GvHD, but their exact role in 
prophylaxis and treatment has not yet been defined. Our current view of the 
pathophysiology of GvHD is summarized in Figure 7.1.  
 
Figure 7.1: Pathophysiology of acute GvHD. 
Pathophysiology of acute GvHD is summarized into three steps. 1. Conditioning 
regimen prior to transplantation damages and activates host tissues, especially 
the intestinal mucosa. DAMPs are released as a consequence; leading to 
inflammatory cytokine release and activation of host APCS. 2. Host APCs 
activate donor T cells in draining lymph nodes. 3. Activated macrophages along 
with T cells secret inflammatory cytokines that cause target cell apoptosis.  
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Our understanding in GvHD biology has advanced substantially; yet, the 
pathophysiology of gut GvHD is poorly understood partially due to the lack of gut 
biopsies for research and the difficulties to directly translate data from murine 
experiments into humans. The aim of this dissertation was therefore to analyze 
immune cell infiltrates and biomarkers in gut biopsies of patients after allogenic 
stem cell transplantation and to explain some of the newer findings on the role of 
the microbiome by analyzing bacterial metabolites in vitro . 
CD4+ T cells and CD8+ T cells were analyzed by means of single antibody 
immunohistochemistry (IHC). CD4+ T cells were found to be correlated with CD8+ 
T cell infiltration and epithelial apoptosis whereas CD8+ T cells were upregulated 
in GvHD and correlated with crypt loss and epithelial apoptosis confirming the 
primacy of T cell infiltrates in development and exacerbation of GvHD.  
Foxp3+ and IDO+ cells were analyzed by IHC in gut biopsies of ASCT patients 
and the respective mRNA expression was analyzed by qPCR. Both Foxp3+ cells 
and IDO+ cells significantly upregulated at protein and mRNA level with 
exacerbation of GvHD, and, Foxp3 and IDO expression strongly correlated to 
each other suggesting an immunoregulatory loop reactively activated to dampen 
the T cell response. Using double immunofluorescence, existence of both, the 
expected CD4+Foxp3+ and the new population of CD8+ Foxp3+ Tregs were 
discovered which may be crucial for GvHD resolution.  
IL-17+ cells were analyzed by IHC and immunofluorescence in colon biopsies of 
ASCT patients which were significantly downregulated in GvHD. In line with 
protein expression, the transcription factor RORC significantly downregulated in 
GvHD. Double immunofluorescence depicted these cells are non T cells but co-
express CD117 (c-kit) confirming the innate origin of IL-17+ cells, more likely to be 
type 3 innate lymphoid cells. This suggests that IL17+ cells beyond TH17 cells 
exist also in humans which may be protective in GvHD by production of protective 
IL22.  
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First phase of gene profiling revealed four possible candidate genes: CYP27A1, 
CYP27B1, VDR and PXR that were highly regulated in GvHD and two genes: 
VDR and CYP27A1 could be a future biomarker. The predominance of Vitamin D 
dependent genes as significant biomarkers in GI tissue further supports the 
central role of immunoregulation in GvHD related inflammation.  
As many of these regulatory loops are activated by the interplay between 
intestinal microbiota and immune cells, we revealed the importance of bacterial 
metabolite indoxyl sulfate as a potential immunomodulator that inhibited 
maturation and activation of human monocyte-derived dendritic cells in vitro.  
Based on our findings we propose a new hypothesis on the pathophysiology of 
GvHD which is shown in fig 7.2 
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Figure 7.2: Pathophysiology of acute GvHD. 
In a steady state, balanced microbiome and microbial metabolites maintains 
epithelial integrity and immune homeostasis. Once microbial diversity is 
destroyed initially due to broad antibiotics, epithelial barrier is broken and at the 
same time, bidirectional communication between Paneth cell and microbiome is 
hampered leading to compromised Reg proteins and defensins. Conditioning 
mediated toxicities leads to production of ATPs and uric acid which work together 
with PAMPs and DAMPs to indcue recipient antigen expression in antigen 
presenting cells. This leads to severe graft vs host reaction with increased CD8+ 
T cell activation. Both CD4+ and CD8+ T cells work synergistically to further 
destroy Paneth cells and epithelium. MDSC, Tregs, IDO+ cells, and toleregenic 
APCs try to dampen the inflammation but due to the lack of beneficial bacterial 
metabolites, complete regulation is obstructed and control of GvHD cannot be 
achieved. Alongside, IL17/IL22 producing protective ILCs, and vitamin D related 
parameters are lost in the course of inflammation. These phenomena lead to 
severe tissue destruction in lethal graft vs host disease. 
 
 
In summary, our data underline that GvHD is a result of an imbalance between 
alloreactive T cells and protective regulatory cells and ILCs. Strategies aiming to 
restore immunoregulation are of central importance and may be either applied 
directly or by changing the balance of microbiota as bacterial metabolites play a 
major role in intestinal immunoregulation. 
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8 Zusammenfassung 
In der Pathophysiologie der GvHD stand bis vor kurzem die Aktivierung 
alloreaktiver zytotoxischer T Zellen des Spenders durch major und minor HLA 
Antigene des Empfängers im Vordergrund. In einer ersten Phase werden diese 
auf Empfänger Antigenpräsentierenden Zellen nach Aktivierung durch die 
Konditionierung und Danger Associated Patterns stimuliert. In der Effektorphase 
werden die Targetorgane der GvHD über zytotoxische Mechanismen, aber auch 
über FasL und von CD4 Zellen produzierte proinflammatorische Zytokine 
geschädigt. Natürliche regulatorische T Zellen können die Entstehung der GvHD 
verhindern bzw abschwächen. 
 
Die exakte Rolle der Immunregulation und der beteiligten Zellpoulationen im 
Patienten bei der GvHD ist z.T. durch die Schwierigkeit der Untersuchungen von 
Biopsien, aber auch durch die mangelnde Übertragbarkeit aus dem Mausmodell 
bisher unzureichend charakterisiert. Ziel dieser Arbeit war es deshalb, an einer 
großen Serie intestinaler Biopsien mittels Immunhistologie und -fluoreszenz 
sowie auf mRNA Ebene die regualatorischen Zellpopulationen genauer zu 
untersuchen und als möglichen Mechanismus der Immurnegaulation die 
Interaktion eines von der Arbeitsgruppe diagnostisch beschriebenen bakteriellen 
Metaboliten mit Immunzellen zu chrakterisieren. 
 
Die Dominanz zytotoxischer T Zellen konnte durch die Korrelation der CD8 
Infiltrate mit der Apoptose bestätigt warden, CD4 Zellen waren im Sinne einer T-
Zellhilfe damit assoziiert. 
 
Anders als erwartet waren Foxp3 positive Zellen und die Foxp3 mRNA bei 
Auftreten einer GvHD heraufreguliert. In Zusammenschau mit der gleichzeitigen 
Aktivierung IDO positive Zellen muss von einer immunregulatorischen Reaktion 
auf die T-Zellaktivierung ausgegangen warden. Als neue Population wurden 
neben den bekannten CD4+Foxp3+ Zellen auch CD8+Foxp3+ Zellen beschreiben, 
die als regulatorische Zellen im intestinalen Gewebe bei anderen Erkrankungen 
bekannt sind. 
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Entgegen der Erwartungen waren IL17 positive Zellen bei der GvHD vermindert. 
Das Paradoxon, dass TH17-Zellen bei der GvHD vermehrt sein sollten, konnte 
dadurch aufgeklärt warden, dass die IL17+ Zellen keine T Zellmarker trugen, 
sondern dass sie wegen der Positivität für cKit vermutlich Innate Lymphoid Cells 
vom Typ 3 sind. Die verminderte Expression des Transkriptionsfaktors RoRy 
unterstützt diese Befunde.Diesen Zellen wird eine wichtige Rolle bei der 
Dämpfung der intestinalen Inflammation, vermutlich über IL22, zugeschrieben.  
 
In der Genexpressionsanalyze stachen Enzyme des Vit D Stoffwechels sowie der 
VitDR als prognostische Marker hervor, was die zentrale Rolle der 
Immunregulation bei der intestinalen GvHD weiter unterstreicht.  
 
Viele dieser regulatorischen Mechansimen warden durch die Interaktion mit dem 
intesitnalen Mikrobiom aktiviert. In der Untersuchung des in der Diagnostik 
wichtigen Indoxlysulfats konnte gezeigt werden, dass dieser Metabolit die 
Aktivierung von Immunzellen supprimiert und zur Immunregaultion über IL10 
führt. 
 
Zusammenfassend zeigen diese Untersuchung auf mehreren Ebenen, dass die 
GvHD als Dysblance zwischen Aktivierung zytotoxischer T Zellen und der 
Suppression regulatorischer Populationen wie T regs und ILCs verstanden 
werden kann. Die Entwicklung von Strategien zur Wiederherstellung der 
Immunregulation scheint von zentraler Bedeutung für die Verbesserung der 
GvHD Porphylaxe und Therapie zu sein. Dies kann entweder direkt geschehen 
oder durch Wiederherstellung einer balanzierten Zusammensetzung der 
intestinalen Mikrobiota, deren Metabolite einen erheblichen Anteil an der 
intestinalen Immunregulation tragen.  
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